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1. INTRODUCTION 
1.1. Definition of idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis (IPF) is the most common group of idiopathic interstitial 
pneumonias. According to the current definition, IPF is associated with a histological 
pattern of usual interstitial pneumonia (UIP). IPF is a chronic, irreversible, progressive 
and usually fatal disease of unknown etiology (King Jr et al., 2011) characterized by 
exertional dyspnea and cough (Selman et al., 2007).  
 
1.2. Epidemiology of idiopathic pulmonary fibrosis  
IPF is a rare disease with prevalence from 14 to 27.9 cases per 100,000 population in 
the USA or 1.25 to 23.4 cases per 100,000 population in Europe using narrow case 
definitions (Antoniou et al., 2013). IPF prevalence and incidence increase with age.  
IPF occurs in middle-aged and older people with the average age at diagnosis 66 
years. Moreover, there is a higher predominance of the disease in males than in 
females (Nalysnyk et al., 2012). Particularly severe forms of pulmonary fibrosis have a 
mean mortality of 2-6 years after diagnosis (Wynn, 2011).    
 
1.3. Risk factors of idiopathic pulmonary fibrosis   
Although IPF is defined a disease of unknown etiology, several potential risk factors 
have been described over the last decades (Raghu et al., 2011). 
 
1.3.1. Cigarette smoking  
Smoking is strongly associated with both familial and sporadic IPF. It applies 
particularly to individuals with smoking history more than 20 pack-years (Iwai et al., 
1994). 
 
1.3.2. Environmental exposures 
The onset and origin of IPF is not fully known (Fernandez and Eickelberg, 2012a). The 
most important environmental risk factors appear to be: smoking (ATS and ERS, 
2002), exposure to metal and wood dust (ATS and ERS, 2000), pollutants, viral 
infections (Lasithiotaki et al., 2011) and ageing (Faner et al., 2012). Farming, raising 
birds, hair dressing, stone cutting/polishing, and exposure to livestock and to vegetable 
dust/animal dust have also been associated with IPF (Baumgartner et al., 1997). 
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1.3.3. Microbial agents 
Viral infection, such as Epstein-Barr virus (EBV), human herpes virus 7 and 8, 
cytomegalovirus and hepatitis C virus (Wuyts et al., 2013), was proposed as initiator of 
IPF. EBV is the most studied virus in this context. EBV protein as well as DNA 
expression has been found in the lung tissue of patients with IPF. Further, a poor 
prognosis in patients with IPF was linked to the expression of EBV latent  membrane 
protein-1 in alveolar epithelial cells (AECs) (Tsukamoto et al., 2000) and EBV-AEC 
interactions might be associated with fibrotic scars appearing during fibrosis (Fukuda et 
al., 2001). Despite of the extensive studies, one can hardly define the role of viral 
infection in IPF due to the variable confounding factors in the patients. 
 
1.3.4. Gastroesophageal reflux (GER) 
The prevalence of GER in IPF is estimated to be up to 90% (Raghu et al., 2006), and 
recent studies have demonstrated the association between acute exacerbations of IPF 
and GER. Considering the high prevalence of GER in normal population as well as 
patients with other advanced lung diseases, further studies are required to understand 
the role of GER in IPF.  
 
1.3.5. Genetic predisposition 
Most of DPLDs diseases are sporadic, however the examples of familial cases exist. 
Familial clustering of adult idiopathic interstitial pneumonias (IIP) suggests that genetic 
factors might play an important role in the disease development.  
 
1.3.5.1. Surfactant protein C (SP-C) gene 
Some patients occur to have mutations in the gene of the surfactant protein C 
expressed by epithelial cells type II (Wuyts et al., 2013). Mutation in SP-C leads to 
incorrect protein folding and ER stress, and alveolar epithelial cell apoptosis accures. 
There are examples of familial occurrence in IPF, although most of these diseases are 
sporadic cases. Van Moorsel and colleagues reported that five out twenty unrelated 
patients with familial pulmonary fibrosis had the mutation of SP-C while this mutation 
was not present in sporadic disease (van Moorsel et al., 2010).  
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1.3.5.2. Mucin 5B (MUC5B) gene 
A polymorphism in the promoter region of mucin 5B gene has been found in familial 
cases as well as in idiopathic IPF (Seibold et al., 2011). Moreover, due to a common 
variant in the putative promoter of MUC5B, the expression of MUC5B was highly 
elevated in the lung of patients suffered from IPF when compared with healthy subjects 
(van Moorsel et al., 2010).  
 
1.3.5.3.  ELMO domain containing 2 (ELMOD2) gene 
ELMOD2 mRNA expression is significantly down-regulated in patients affected by IPF 
in comparison to healthy subjects. Further, ELMOD2 has been shown to be implicated 
in the regulation of interferon-related antiviral responses (Pulkkinen et al., 2010). 
 
1.3.5.4. Telomerase gene 
Telomeres are a molecular cap of noncoding DNA which protect the chromosome ends 
against degradation. Telomeres become shorter during repeated cell division. A 
complex of proteins and RNA named telomerase is required in maintaining telomere 
length: the reverse transcriptase component (TERT) and the telomerase RNA template 
component (TERC) are key components of the telomerase complex. Mutations in 
TERC and TERT account for 8-15% of familial and 1-3% of sporadic cases. The short 
telomere length is more often found in IPF even in the absence of telomerase 
mutations (Spagnolo et al., 2012).  
 
1.4. Classification of diffuse parenchymal lung diseases (DPLD) and diagnosis of 
interstitial lung fibrosis (IPF) 
The idiopathic interstitial pneumonias (IIPs), also described as interstitial lung diseases, 
belong to DPLDs (Figure 1). The IIPs are characterized by heterogeneous group of 
nonneoplastic disorders resulting from damage to the lung parenchyma by different 
patterns of inflammation and fibrosis. The space between the epithelial and endothelial 
basement membranes is called the interstitium which is the primary site of injury in 
IIPs. However, these disorders often affect not only the interstitium, but also the 
peripheral airways, airspaces, as well as vessels along with their respective epithelial 
and endothelial linings (Raghu et al., 2011). 
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Figure 1. Current classification of diffuse parenchyma lung diseases (ATS and ERS, 2002). DPLD: 
diffuse parenchymal lung disease; IIP: idiopathic interstitial pneumonias; LAM: lymphangioleiomyomatosis; 
HX: histiocytosis/histiocytosis. 
 
1.5. Clinical, radiological and histological features of pulmonary fibrosis  
To establish uniform definitions and criteria for the diagnosis of IPF, multidisciplinary 
approach is required, including the cooperation of clinicians, radiologists and 
pathologists (Flaherty et al., 2004). For the final diagnosis, a pattern of IIPs on high-
resolution computed tomography (CT) or on lung tissue obtained by surgical lung 
biopsy is crucial (Travis et al., 2013). During the last 30 years the pathological 
description of  IPF has been rearranged, and the most current classification was 
represented by American Thoracic Society and European Respiratory (Travis et al., 
2013). 
 
1.5.1. Clinical characteristic of pulmonary fibrosis: 
1. Gradual dyspnea, nonproductive cough (ATS and ERS, 2000). 
2. Digital clubbing appears in 20 to 25% of patients (ATS and ERS, 2002). 
3. A pattern of ventilatory defect with decreased DLCO and low resting PaO2 which 
drops during exercise (Pérez et al., 2010). 
4. Classic clinical phenotype is slowly progressive in decrease of lung function and 
worsening dyspnea; some patients present a rapidly progressive disease (< 6 months 
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of symptoms before first presentation) and display shorter survival, mainly the men who 
smoke heavily cigarettes. A gene expression profile differs in these both groups, 
although the lung function, chest imaging and histology were similar (Ley et al., 2011). 
5. There is increased level of neutrophils in bronchoalveolar lavage fluid (BALF). It also 
contains mild increase in percentage of eosinophils. Lymphocytosis is not a feature of 
UIP. Moreover, BALF cell count correlates with the severity of disease, however does 
not predicts prognosis (Wells et al., 1994). 
 
1.5.2. Radiological characteristics of pulmonary fibrosis 
1. On chest radiograph: the peripheral, reticular opacity appears, most visible at 
the basis, often associated with honeycombing. The chest radiography can 
occasionally be normal in IPF patients. 
2. On computed tomography (CT): the abnormality in IPF patients is reticular 
opacity, often associated with traction bronchiectasis and little or no ground-
glass opacifications; honeycombing is common. The distribution of UIP is 
noticed at the bases and periphery but often patchy (Figure 2a and 2b). 
3. The architectural distortion is often prominent and lobar volume loss is 
observed in advanced fibrosis (King Jr et al., 2011). 
 
1.5.3. Histologic characteristics of pulmonary fibrosis 
1. There is temporal heterogeneous appearance with alternating zones of 
abnormal and healthy lung tissue (Figure 2c, asterisk). 
2. Interstitial inflammation is mild and associated with hyperplasia of epithelial 
cells type II. 
3. The temporal heterogeneity in the fibrotic zones is indicated by the presence of 
dense a cellular collagen and juxtaposed with fibroblastic foci of loose 
connective tissue (Figure 2c, arrows). 
4. Fibroblast foci are small areas of active fibrosis present in the background of 
collagen deposition, and they reflect the temporal heterogeneity of the disease. 
5. Area of honeycomb consist of cystic fibrotic airspaces (Figure 2d) are lined with 
bronchiolar epithelium and often filled by mucin and various number of 
inflammatory cell. 
6. There is no single histological feature that can be correlated with the prognosis 
of IPF or the response to the treatment (Travis et al., 2013). 
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Figure 2. The typical pattern of usual interstitial pneumonia (UIP) on high-resolution computed 
tomography  (HRCT) (King Jr et al., 2011). There are zones of abnormal and healthy lung tissue (Figure 
2c, asterisk), presence of dense cellular collagen and juxtaposed with fibroblastic foci of loose connective 
tissue (Figure 2c, arrows). 
 
1.6. Pathogenic events initiate and promote pulmonary fibrosis 
The precise mechanisms that drive the development of pulmonary fibrosis remain 
incompletely understood, however three broad areas such as inflammation, oxidative 
stress, coagulation disturbances (Figure 3) have been investigated. They may be 
responsible for altered lung fibroblast phenotype, apoptosis of epithelial cells and 
excessive production of ECM (Todd et al., 2012).  
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Figure 3. Schematic diagram of three broad mechanisms that result in pulmonary fibrosis following 
lung injury (Todd et al., 2012). 
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1.6.1. Endoplasmic reticulum (ER) stress 
Endoplasmic reticulum (ER) stress in alveolar epithelial cells is prominent in IPF. Not 
only does it cause alveolar epithelial cells apoptosis, it also serves as a fibrotic stimulus 
by promoting epithelial-mesenchymal transition (EMT) and inflammatory responses 
(Tanjore et al., 2013). ER stress is caused by events that disturb the processing and 
folding of proteins, which results in the accumulation of misfolded proteins in the ER 
and activation of the cellular response termed as unfolded protein response (UPR). 
Mammalian cells have three sensors of unfolded proteins: IRE1α (inositol requiring 
enzyme 1α), PERK (protein kinase RNA-like ER kinase), and ATF6 (activating 
transcription factor 6) which, when activated, initiate the UPR (Wolters et al., 2014). 
Many studies have shown that the markers of UPR activation, for example CHOP 
(CCAAT/enhancer-binding protein (C/EBP) homologous protein), p50ATF6 (the 
processed form of ATF6), BiP (binding immunoglobulin protein) and IRE1α, are 
increased in alveolar epithelial cells of IPF patients (Korfei et al., 2008). Many causes 
of ER stress were found in IPF patients. Expression of the G231V or F198S mutant of 
SP-A in epithelial cells causes the elevated level of BiP and XBP1s (Maitra et al., 
2010). However, mutants SP-A and SP-C only present in 5% of IPF patients. There are 
other factors contributing to the ER stress. For example, herpesvirus protein 
expression was shown to co-localize with UPR markers, suggesting that ectopic 
production of viral proteins can activate the UPR (Lawson et al., 2008).  
 
1.6.2. Oxidative stress 
Oxidative stress is termed as imbalance in generating reactive oxygen species (ROS) 
in excess of a capacity to neutralize them. ROS overproduction may lead to oxidative 
stress that causes tissue injury. The key origins of oxidative stress in pulmonary 
fibrosis are environmental toxins, depletion of antioxidant defenses, mitochondria/ 
NADPH oxidase of inflammatory and lung target cells (Cheresh et al., 2013). This 
stress may initiate a tissue microenvironment which favors fibrosis against regeneration 
of lungs. This may be an important factor for fibroblast to develop resistance to 
apoptosis. Many papers demonstrated that myofibroblasts secrete hydrogen peroxide 
which can mediate fibrogenic effects and induce epithelial apoptosis (Waghray et al., 
2005). Further, NADPH oxidase 4 is up-regulated in fibroblast foci from IPF patients. 
NADPH oxidase 4 is induced by TGF-β in mesenchymal cells isolated from IPF 
patients and is involved in ECM production, myofibroblast differentiation and 
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1.6.3. Coagulation disturbance 
Accumulating evidence has shown a disturbed coagulation cascade in patients with 
pulmonary fibrosis. The coagulation cascade plays a crucial role in inflammatory and 
tissue repair programs during wound healing in response to injuries. The cellular 
responses of the coagulation cascade are principally executed by several pro-
coagulant proteinases such as tissue factor, factor XII or thrombin, all of which are 
elevated in bronchoalveolar lavage fluid (BALF) or alveolar epithelial cells (AECs) of 
IPF patients (Günther et al., 2000; Imokawa et al., 1997). Moreover, proteinase-
activated receptor 1 and receptor 2 (PAR1 and PAR2) are activated in various lung cell 
types such as pulmonary epithelial cells, macrophages, and fibroblasts leading to 
activation and release of potent proinflammatory and profibrotic mediators (Wuyts et 
al., 2013; Wygrecka et al., 2011). On the other hand, the fibrinolytic activity was 
compromised by increased antifibrinolytic plasminogen activator inhibitors (PAIs) 
(Kotani et al., 1995). 
 
1.6.4. Inflammation 
1.6.4.1. Pro arguments- pulmonary fibrosis is an inflammatory disease 
The concept that dominated in the 1970s and 1980s described pulmonary fibrosis as 
‘chronic inflammatory disease of the lung parenchymal’ and explained that chronic 
pulmonary inflammatory injures modulate fibrogenesis and lead to fibrotic scares. This 
paradigm was based on  increased level of inflammatory cells from the BAL fluid of IPF 
patients when compared with healthy individuals (Homer et al., 2011). Considering the 
fact that numerous cytokines play a role in pulmonary fibrosis, and inflammatory cells, 
although not exclusively, are one of the major source of cytokines, inflammation is 
relevant to triggering the disease. Macrophages are involved in all stages of fibrosis. 
Studies showed that if macrophages were depleted during the early phase of fibrosis, 
scarring was reduced and the number of myofibroblasts was decreased. In contrast, if 
the macrophages were depleted during late-remodeling phase of fibrosis, the disease 
was not attenuated (Wynn and Barron, 2010). There are also studies showing that 
CD4+ lymphocyte- Th1 and Th2 play important role in the inflammatory phase of lung 
fibrosis (Todd et al., 2012). 
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1.6.4.1.1. Lymphocytes 
After injury, epithelial cells release IL-25 and IL-33 which can facilitate the development 
of profibrotic Th2 response. T cells also secrete IL-21 and IL-25 which promote Th2 
differentiation (Fulkerson et al., 2006). However, Th2 cytokines can also trigger 
antifibrotic feedback. For instance, arginase-1 in M2 macrophages is activated by Th2 
cytokines and the production of IL-13 and myofibroblasts differentiation is inhibited. 
IFN-γ, secreted by Th1 lymphocytes, suppresses collagen synthesis by fibroblasts and 
promotes the activation of M1 macrophages that promote ECM degradation 
(Ramalingam et al., 2008). 
 
1.6.4.1.2. Macrophages 
M1 macrophages are induced by interferon gamma (IFN-γ) and identified by 
expression of interleukin IL-12, tumour necrosis factor (TNF) and C-X-C motif 
chemokine 10 (CXCL10). They are implicated in extracellular matrix (ECM) 
degradation, thus resolving fibrosis. M2 macrophages are induced by IL-4 and/or IL-13 
and express IL-1 RII, mannose receptors, hemoglobin scavenger receptor CD163 and 
many others (Homer et al., 2011). They are involved in releasing EMC components 
and developing fibrosis.  
 
1.6.4.2. Con arguments- pulmonary fibrosis is not an inflammatory disease 
The concept seems to be currently challenged. The recent hypothesis presents that 
fibrosis results from repetitive epithelial injures and abnormal wound healing and it is 
rather an ‘epithelial-fibroblastic’ disease rather than an inflammatory disorder (Selman 
et al., 2001). First, inflammation is not essential for the development of fibrosis. For 
instance, IL-10 KO mice in silica-induced fibrosis, presented more severe lung 
inflammation but less fibrotic response in comparison to wild mice.  Moreover, fibrosis 
develops without inflammatory phase when mice were exposed to 95% hyperoxia and 
lung explants were cultured in hyperoxic, blood-free environment. Moreover, fibroblasts 
proliferation and collagen deposition  increased (Selman et al., 2001). Second, failure 
of anti-inflammatory therapies in disease outcome. There is not the recommendation 
for treatment with interferon gamma-1b because  the drug did not improve survival for 
patients with IPF (King Jr et al., 2009). Third, there is the lack of correlation of 
inflammatory markers with progression of the disease. In various diffuse infiltrative 
diseases, the extent and severity of ground-glass opacities correlate with alveolitis. 
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However, in IPF they are not associated with the inflammatory response (Reynolds, 
2005). 
 
1.7. Cellular pathobiology  
Myofibroblasts highly express α-smooth muscle actin (α-SMA) and secrete massive 
extracellular matrix (ECM) components such as collagen. In the wound remodeling 
phase, myofibroblasts initiate wound contraction, a process where the edges of the 
wound migrate toward the center, epithelial/endothelial cells divide and migrate over 
the temporary matrix to regenerate the damaged tissue. Fibrosis appears when the 
wound is severe, the tissue-damaging irritant persists for long time, or when the repair 
process becomes dysregulated (Wynn, 2011). Similarly to cancer, myofibroblasts can 
maintain their own growth by producing several cytokines such as TGF-β and losing 
the capability to produce the antifibrotic PGE2 (prostaglandin E2) (Moore et al., 2005). 
The origin of myofibroblasts remains unclear (Willis et al., 2005). There are three 
theories that seek to explain the origin of myofibroblasts: 1) activated resident lung 
fibroblasts, 2) epithelial cells via the process of epithelial-mesenchymal transition 
(EMT) or 3) bone marrow–derived fibrocytes (Figure 4).   
 
 
 
Figure 4. Overview of the sources of recruitment of fibroblasts during the development of 
idiopathic pulmonary fibrosis (King Jr et al., 2011).  
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1.7.1. Residental fibroblasts 
The increased number of myofibroblasts in the subepithelial injured area and in the 
fibroblastic foci is caused by the fact that resting resident fibroblasts become activated, 
proliferate, and differentiate into highly contractile myofibroblasts in response to 
profibrotic growth factors, for instance transforming growth factor beta (TGF-β) or  
platelet-derived growth factors (PDGFs) (Fernandez and Eickelberg, 2012b). TGF-β 
promotes fibroblast and macrophage recruitment as well as fibroblast proliferation via 
PDGF expression. In these cells, TGF-β also stimulates expression of various 
proinflamatory and fibrogenic cytokines, such as TNF-a, PDGF, IL-1 or IL-13, thereby 
further enhancing and maintaining the fibrotic response (Fernandez and Eickelberg, 
2012b). 
 
1.7.2. Epithelial-mesenchymal transition (EMT) 
EMT mostly known for its crucial role in tumor cell invasion and metastasis in many 
cancer diseases (Trovato-Salinaro et al., 2006). In the last decade, an increased 
number of studies indicate that alveolar epithelial cells undergo EMT under the 
profibrotic environment after the injury, and contribute to the myofibroblast population 
(Vancheri, 2012, (Willis et al., 2006) in the fibrotic lungs. More importantly, attenuated 
pulmonary fibrosis was observed in animal models by blocking the EMT process 
(Aoyagi-Ikeda et al., 2011). A few molecules have been suggested in the EMT process, 
with TGF-β and Wnt being highlighted. It has been shown that the epithelial cells 
stimulated with TGF-β or Wnt lose epithelial markers: cytokeratin and E-cadherin and 
express mesenchymal markers: vimentin, collagen type I and α-SMA (Lamouille et al., 
2014); Vancheri et al., 2010).  
 
1.7.3. Fibrocytes 
Another important source of lung myofibroblast are bone marrow-derived mesenchymal 
progenitor cells called fibrocytes. They are the subpopulation of leukocytes expressing 
both haemopoietic (CD45, CD34) and mesenchymal (collagen I, fibronectin) cell 
markers (Strieter et al., 2009). Some studies have elucidated that fibrocytes account for 
20% of cells which contribute to lung fibroblasts (Tanjore et al., 2009). Similar to 
resident fibroblasts and epithelial cells, fibrocytes respond to TGF-β–driven 
differentiation into myofibroblast through activation of Smad2/3, SAPK/JNK and MAPK 
signal transduction (Hong et al., 2007). In addition, the human fibrocytes express the 
chemokine receptor CXCR4 (chemokine (C-X-C motif) receptor 4), whereas epithelial 
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cells from the IPF patients upregulate CXCL12 (C-X-C motif chemokine 12), which 
probably induces the chemotactic gradient required for trafficking of CXCR4 positive 
fibrocytes (Andersson-Sjöland et al., 2008). This cooperation suggests that the 
CXCR4-CXCL12 biological axis is important for recruiting circulating fibocytes into lung 
during the pathogenesis of pulmonary fibrosis (Andersson-Sjöland et al., 2008).  
 
1.8. Molecular pathobiology of interstitial lung fibrosis (IPF) 
There is a multiple-pathway mechanism that plays the role in the pathogenesis of IPF. 
A range of molecular abnormalities that can result in fibrosis are well characterized. 
The TGF-β signaling pathway is the best known in pulmonary fibrosis, however, there 
is not only one pathway that is implicated in the development of IPF (Figure 5). 
 
 
 
 
Figure 5. A new model for the pathogenesis of idiopathic pulmonary fibrosis (Maher et al., 2007). Th: 
T-helper cell; CTGF: connective tissue growth factor; TGF-β: transforming growth factor-β; PDGF: platelet-
derived growth factor; FXa: factor Xa; PG: prostaglandin; IFN-γ: interferon-γ; EMT: epithelial–
mesenchymal transition. 
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1.8.1. Transforming growth factor beta (TGF-β) signaling pathway 
More than 60 members of TGF-β family are known: five activins, eight bone 
morphogenetic proteins (BMPs) and three TGF-βs (Feng and Derynck, 2005). The 
three mammalian TGF-β isoforms: TGF-β1, 2 and 3 are synthesized as latent 
precursor molecules (LTGF-β) containing an amino-terminal hydrophobic signal 
peptide region, the latency associated peptide (LAP) region and the C-terminal 
potentially bioactive region (Roberts, 1998). The LTGF-β creates the complexes with 
latent TGF-β-binding proteins (LTBP) and requires activation into a mature form for 
receptor binding and activation of signaling pathway. The LTBP is removed 
extracellularly due to a cleavage by plasmin, thrombin, plasma transglutaminase or 
endoglycosylases, or due to physical interactions of the LAP with thrombospondin-1 
(Annes et al., 2003).  
The secreted TGF-β binds to two different types of serine/threonine kinase receptor: 
type I and type II (Figure 6). In vertebrates, there have been identified five type II and 
seven type I receptors that are referred to as activing- receptor-like kinase (ALKs) (ten 
Dijke and Hill, 2004). Both receptors are present as homodimers in the plasma 
membrane. Upon ligand binding, the type II receptors activate the type I receptor 
kinases through phosphorylation of the juxtamembrane domain (the Gly/Ser-rich 
domain or GS domain) of type I receptors. Further, the type I receptos activate the 
signal messengers belonging to Smad family (Marcelo Ehrlich, 2012).   
Smads are divided in three subclasses: receptor-regulated Smads (R-Smads), 
common partner Smads (Co-Smads) and inhibitory Smads (I-Smads). In mammals, 
Smad2 and Smad3 act as TGF-β/activin-specific R-Smads; Smad1, Smad5 and, 
presumably, Smad8 are BMP-specific R-Smads. Smad4 is the only Co-Smad;  Smad6 
and Smad7 act as I-Smads (Miyazono, 2000).  
R-Smads are anchored to the cell membrane through membrane-bound proteins such 
as Smad-anchor for receptor activation (SARA). Phosphorylated Smads-R form 
heteromeric complexes with Co-Smad- Smad4 and enter to the nucleous where they 
serve as transcriptional factors with the coactivators CBP and p300. Further, inhibitory 
Smads antagonize signaling pathway, so they act in opposing manner to R-Smads. 
They compete with R-Smads for binding to TGF-β RI and inhibit the phosphorylation of 
R-Smads and/or TGF-β RI degradation by E3-ubiquitin ligases (Shi and Massagué, 
2003).  
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Figure 6.  Transforming growth factor beta (TGF-β) transduction pathway (Verrecchia and Mauviel, 
2007). 
 
1.8.2. Connective tissue growth factor (CTGF) 
CTGF plays a central role in pulmonary fibrosis. CTGF induces formation of 
myofibroblasts through transdifferentiation of different types of cells, including epithelial 
cells (via EMT, epithelial to mesenchymal transition), stellate cells, resident fibroblasts 
or fibrocytes (bone-marrow-derived, circulating mesenchymal stem cells) that have 
been recruited to an organ through chemokines. CTGF also activates the 
myofibroblasts and stimulates their deposition and remodeling of ECM (extracellular 
matrix) proteins. Moreover, CTGF activates the production of a variety of cytokines 
such as TGF-β (Yang et al., 2010) and VEGF, which induce higher expression of 
CTGF (Lipson et al., 2012).  
 
1.8.3. Integrins 
Various integrins have been found in inflammatory cells during pulmonary fibrosis. 
Many T cells express αEβ7, which is elevated by TGF-β, and binds to E-cadherin on 
epithelial cells (Kilshaw, 1999). Additionally, lymphocytes and eosinophils may express 
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α4 integrins which binds to vascular cell adhesion molecule-1 (VCAM-1). In the 
bleomycin model, treatment with neutralizing antibody against α4 showed diminished 
hydroxyproline contenst, histologic fibrosis, cellular inflammation, and α-SMA 
expression (Todd et al., 2012). Integrins which are expressed on fibroblasts can 
activate latent TGF-β as well as promote fibrosis. Moreover, the α2β1 integrin is a main 
type I collagen receptor (Jokinen et al., 2004).  
 
1.8.4. Interleukin-13 (IL-13) 
Cytokines associated with CD4+ Th1 and Th2 cells have elicited contrasting activity in 
fibrogenesis. Interleukin-13 (IL-13) is the Th2-associated cytokine and is linked to the 
development of the fibrosis. Moreover, IL-13 is detected in the BAL fluid of IPF 
patients; the hyperresponsiveness of IPF fibroblasts to IL-13 and expression of both IL-
13 and IL-13Rα1 correlates with the severity of the disease (Murray et al., 2008). 
Further, fibroblasts isolated from the lungs of patients affected with IPF exhibit an 
increase in IL-13 receptor expression for both IL-13Rα1 and IL-13Rα2 (Clarke et al., 
2013). 
 
1.8.5. Platelet-derived growth factor (PDGF) 
The importance of PDGF signaling in the fibrotic process is presented by reports 
showing that a number of fibrogenic mediators such as TGF-β, IL-1, TNF-α, bFGF, and 
thrombin exhibit PDGF-dependent profibrotic activities. PDGF induces fibroblast 
chemotaxis, fibroblast proliferation and promotes fibroblast-mediated tissue matrix 
contraction  (Bonner, 2004). The expression of two PDGF isoforms, PDGF-C and 
PDGF-D, increases during bleomycin-induced lung fibrosis and it has been shown that 
PDGF receptor tyrosine kinase inhibitors markedly attenuate radiation-induced 
pulmonary fibrosis (Zhuo et al., 2004). 
 
1.8.6. Wnt 
The activation of canonical and noncanonical TGF-β signal transduction is involved in 
myofibroblast differentiation by promoting stress fiber formation (Sousa et al., 2007). 
Akhmetshina and collegues showed that the crosslink between TGF-β and Wnt 
pathway is a pivotal factor for fibroblast activation in fibroblast diseases.   
During TGF-β-induced myofibroblast differentiation, canonical  Wnt signaling is 
activated by decrease expression of Dickkopf-1, a Wnt inhibitor, in p38-dependent 
manner and in turn TGF-β requires canonical Wnt activation for fibrosis induction 
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(Akhmetshina et al., 2012). In IPF, additional to canonical activation, Wnt/ β-catenin 
pathway might be activated by TGF-β via the phosphorylation of ERK1/2 leading to a 
secondary activation of other transduction pathways that may regulate cell proliferation 
and apoptosis (Caraci et al., 2008). Several studies have shown that some pathways 
are disregulated in pulmonary fibrosis and can explain aberrant behavior of epithelial 
cells. Wnt/β-catenin is up-regulated in patients with IPF. Moreover, a nuclear 
accumulation of β-catenin in epithelial cells and fibroblasts suggests that this pathway 
is switched on in both types of cells (King Jr et al., 2011). When Wnt pathway is 
blocked by WISP1-neutralizing antibodies, the development of bleomycin-induced 
fibrosis is inhibited (Königshoff et al., 2009).  
 
1.9. Animal models of pulmonary fibrosis 
1.9.1. Bleomycin 
The bleomycin-induced fibrosis is the most widely used animal model of experimentally 
induced pulmonary fibrosis. This model is applied in many species: rats, guinea pigs, 
hamsters, dogs, rabbits, primates, but mice are the most frequently used animals. 
Bleomycin can be delivered in different manners including: intraperitoneal, 
subcutaneous, intravenous, inhalational and intratracheal (Degryse and Lawson, 
2011), all of which induces DNA strand breaks, oxidative stress and the generation of 
free radicals (Moeller et al., 2008). This results in epithelial injury and acute 
inflammation followed by sustained low level of inflammation and development of 
fibrosis. Various cell types, including fibrocytes, fibroblasts, myofibroblasts, 
macrophages, lymphocytes, neutrophils, AECs type I and II, pericytes as well as 
endothelial cells, have been implicated to contribute to bleomycin-induced fibrosis 
(Degryse and Lawson, 2011). Although the histopathology is not fully consistent with 
UIP, the intratracheal delivery of a single dose is the most common route to induce 
pulmonary fibrosis, with alveolar epithelial cells (AECs) on the front line of the injury 
(Molina-Molina et al., 2007). In the intratracheal model, pulmonary fibrosis can be 
established in a short period (2-4 weeks) and the acute inflammatory phase appears 
within the first week; therefore drug intervention during this phase is often protective. 
To study the effects of antifibrotic agents, the therapy should be delivered after the 
inflammatory phase (at least 7 days after bleomycin). Further, C57Bl/6 strain mice are 
known to be more susceptible to bleomycin than Balb/c mice (Moeller et al., 2008).  
Degryse and colleagues have compared the effect of repetitive and single dose of 
bleomycin in intratracheal bleomycin model. Bleomycin was deliverd for 8 weeks, 
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biweekly with the dose of 0.04 units. This model reveled a prominence of hyperplastic 
AECs lining the areas of fibrosis with the similarity to usual interstitial pneumonia (UIP) 
and reduced inflammatory cells in BAL in comparison to single dosing of bleomycin. 
Fibrosis remains prominent 20 to 30 weeks after the last bleomycin dose (Degryse et 
al., 2010).  
In the case of systemic delivery, pulmonary vascular endothelium is the initial site of 
injury, which complicates the model with sustained systemic injury, and pulmonary 
fibrosis develops over a longer time (4 -12 weeks) compared with the intratracheal 
model. For the systemic administration of bleomycin, 20 mg/kg of bleomycin was 
administrated twice weekly for 4 to 8 weeks by intravenous route. It resulted in initial 
endothelial injury followed by epithelial injury, inflammation and fibrosis. The disease is 
developed by week 4, with the progression through week 12 when the mice were 
treated for 8 weeks. The bleomycin at dose 0.035 U/g was delivered twice per week by 
intraperitoneal injections and lung were harvested after 33 days after first dose.  
Subcutaneous delivery of 0.05 mg bleomycin three times per week for 4 weeks is other 
repetitive-dosing option. Bleomycin can be also delivered by miniosmotic pumps, 
presenting other mean of subcutaneous route (B. Moore et al., 2013). In Figure 7, the 
histological pattern typical for various routes of bleomycin instillation is presented.  
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Figure 7. Different manners of bleomycin administration (B. Moore et al., 2013). (A) Trichome blue–
stained lung sections from normal wild-type C57BL/6 mice. (B) Lung section at 3 weeks after 0.08 of a unit 
of intratracheal bleomycin demonstrates the development of an area of fibrosis which is typical for this 
model. (C) Lung section from a mouse at 2 weeks after the eighth biweekly repetitive intratracheal 0.04-
unit bleomycin dose. Arrow points to hyperplastic AECs. (D) Lung section from a mouse harvested on day 
33 in a twice-weekly intraperitoneal 0.035-U/g bleomycin study. Arrowhead points to pleural edge.  
 
1.9.2. Silica 
Silica is accumulated in lung and induces persistent, toxic and inflammatory response. 
In a long term, fibrotic nodules appear around silica deposits which can be easily found 
by polarization microscopy and histologically (Oberdorster, 1996). There are various 
routes of silica delivery: aerosolization, intratracheal administration or oropharyngeal 
aspiration. However, inhalation models mimic human exposure but require longer time 
to develop pulmonary fibrosis (40-120 days) in comparison to the intratracheal models 
(14-28 days) (Lakatos et al., 2006). There is strain-dependent response to silica 
instillation: C57Bl/6 mice are more susceptible than CBA/J mice after 
intratracheal administration of silica; Balb/c mice are resistant in the 
aerosolized model, whereas C3H/HeN, MRL/MpJ, and NZB mice show strong 
response (Davis et al., 1998). It is an important model for investigating the innate 
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immune regulation of lung fibrotic responses because silicosis involves the 
strong influence of macrophage NACHT and LRR, PYD domains-containing 
protein 3 (NALP3) inflammasome activation (Cassel et al., 2008). 
 
1.9.3. TGF-β overexpression 
The expression of many cytokines such as TGF-β1, TGF-α, IL-13, TNF-α and IL-1β 
promotes lung fibrosis (Borthwick et al., 2013; Agostini and Gurrieri, 2006). However, 
TGF-β1 overexpression is studied comprehensively, considering its significant 
profibrotic potency. TGF-β1 overexpression was first carried out in rats by adenoviral 
transfection (Sime et al., 1997), where the expression of TGF-β1 was associated with 
cell infiltration (day 3–7) and the development of alveolar consolidation. Moreover, lung 
collagen concentration was elevated 2-fold by day 14 (Sime et al., 1997). In the 
doxycycline-inducible mice model, epithelial cell specific overexpression of TGF-β1 
driven by Clara cell 10 promoter led to a transient epithelial apoptosis and resulted in 2-
fold increase in collagen concentration over the course of 2 months. Further, the 
established fibrosis resolved after doxycycline withdrawal (Lee et al., 2004). Both 
models involve myofibroblast accumulation, alveolar epithelial cell apoptosis, and the 
induction of epithelial-mesenchymal transition (EMT) (Pulichino et al., 2008). 
 
1.10. Treatment options for IPF 
Until recently, no pharmacological treatment has been clinically proven for the 
treatment of IPF. Lung transplantation is the only therapy that prolongs survival in 
advanced IPF. However, many patients with IPF die before receiving a transplant 
because they are diagnosed at the late stage. Due to the evolving understanding of the 
pathogenesis and disappointing clinical outcome of anti-inflammatory and 
immunosuppressive treatments, there was a shift of paradigm that IPF is an epithelial 
injury-initiated fibrogenesis rather than an inflammation-driven event (Selman et al., 
2001). More recently, two new drugs, pirfenidone and nintedanib, have shown efficacy 
on disease progression and were licensed for the treatment of IPF. Pirfenidone is the 
first approved drug for IPF by EMA (The European Medicines Agency) in 2010 (The 
European Medicines Agency, 2010), followed by FDA (The U.S. Food and Drug 
Administration) approval in 2014 (The U.S. Food and Drug Administration, 2014a). 
Pirfenidone was reported to exhibit antifibrotic, anti-inflammatory, and antioxidant 
effects, although its precise mechanism is not completely clear. Nintedanib, a small 
molecule tyrosine kinase receptor inhibitor which is originally identified for cancer 
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treatment, has shown high anti-fibrotic efficacy (Wollin et al., 2015) and was approved 
by FDA in 2014 (The U.S. Food and Drug Administration, 2014b). Despite of the 
success with pirfenidone and nintedanib, potential targets of multiple pathways in IPF 
gain increasing interest of investigators. A summary of such therapeutic targets is 
outlined in Table 1. 
 
Table 1. Overview of negative phase III randomized controlled trials in IPF 
Compound Mechanism of action Outcome Primary 
endpoint (PE) 
Ambrisentan 
(ARTEMIS) 
Selective inhibitor, an 
endothelin A receptor 
antagonist 
Increased risk of 
hospitalisation due to the 
increase risk for disease 
progression (Raghu et al., 
2013) 
Death or 
disease 
progression 
Bosentan 
(BUILD-3) 
Non-selective inhibitor, 
an endothelin-1 receptor 
antagonist 
No treatment effects in health-
related quality of life or 
dyspnea (King et al., 2011), 
Death or 
disease 
progression 
IFN-ϒ Immunoregulatory 
cytokine 
Lack of improve survival for 
patients with IPF (King Jr et al., 
2009) 
Death or 
disease 
progress 
Imatinib Tyrosine kinase inhibitor No improvement of survival or 
lung function in patients 
effected by IPF (Daniels et al., 
2010) 
Time to disease 
progression or 
death over 96 
weeks 
N-
acetylcysteine 
(NAC) 
Precursor of the 
antioxidant glutathione, 
stimulator of  glutathione 
synthesis 
No significant benefit with 
respect to the preservation of 
FV with mild-to-moderate 
impairment in lung function in 
IPF patients (Raghu et al., 
2014) 
Change in FVC 
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Table 1. (continued) 
Sildenafil Phosphodiesterase-5 
inhibitor 
No significant difference 
between groups  (Zisman et 
al., 2010) 
20% increase 
in 6MWD at 12 
weeks  
 
Warfarin  Anticoagulant Increased risk of mortality in 
an IPF population who lacked 
other indications for 
anticoagulation (Noth et al., 
2012) 
Change in FVC 
 
1.11. Heat shock protein 90 (HSP90) 
HSP90 is an evolutionary conserved chaperone that takes part in late-stage 
maturation, stabilization and activation of more than 200 proteins. It participates in 
various cellular processes including cell cycle control, hormone signaling, cell survival, 
trafficking and response to cellular stress (Wandinger et al., 2008).  
In eukaryotes, HSP90 is found in the cytoplasm, nucleus, and organelles. In Homo 
sapiens, two cytosolic isoform exist: inducible-HSP90α and constitutive-HSP90β. 
Those two isoform are encoded by two different genes and share approximately 81% 
of homology. Moreover, organelle-specific HSP90 forms exist in mitochondria (TRAP1-
tumour necrosis factor receptor-associated protein 1), endoplasmic reticulum (GRP94-
glucose-regulated protein 94) and chloroplasts (HSP90C) (Miyata et al., 2012). Both 
GRP94 and TRAP1 have ATPase activity but lack known co-chaperons (Dollins et al., 
2007). HSP90α is also secreted from the cells or expressed on cell surface, however 
there are mostly associated with cancer cells.  
 
1.11.1. Structure of HSP90 
Hsp90 forms a dimer at physiological conditions.The chaperone structure consists of 
three highly conserved domains: N-terminal domain (NTD), middle-domain (MD) and 
C-terminal domain (CTD). Some members of HSP90 family including cytosolic 
eukaryotic HSP90 and Grp94 have a charged linker which separates NTD and MD. 
Additionally, cytosolic eukaryotic HSP90 has a C-terminal extension of MEEVD (Figure 
5) (Taipale et al., 2010).  
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Figure 8. The scheme of the Hsp90 structure (Whitesell and Lindquist, 2005). The numbering 1–732 
indicates the approximate positions in the amino acid sequence of the human protein that define its 
functional domains. 'CR' refers to a charged region which serves as a flexible linker between the N-
terminal and middle domains. The locations where various small molecules bind HSP90 (heat-shock 
protein of 90 kDa) and modulate its function are indicated. The biochemical functions of each domain are 
also shown. 17AAG:17-allylaminogeldanamycin; GA, geldanamycin. 
 
The NTD contains an ATP and drug-binding site (for geldanamycin and ansamycin) 
and co-chaperone-interacting motifs (for p50 and p23). The MD presents docking sites 
for client proteins such as Akt, Cdk4, eNOS and co-chaperons such as activator of 
Hsp90 ATPase (Aha1) and is associated with forming the active ATPase. The CTD is 
essential for Hsp90 dimerization and possesses a second drug-binding site and 
interaction regions for other co-chaperons (Wayne and Bolon, 2007; Miyata et al., 
2012). 
 
1.11.2. Co-chaperons of HSP90 
Co-chaperons are the proteins which assist or change the function of other chaperons 
(Zhao et al., 2005). The cell division cycle 37 homologue (CDC37), prostaglandin E 
synthase 3 (p23), activator of HSP90 ATPase 1 (AHA1) and  STIP1 (p60HOP) regulate 
the rate of HSP90 cycle by influencing the conformational dynamics of HSP90 (Smith 
and Workman, 2009). Further, some co-chaperons are adaptors which deliver specific 
substrates for HSP90. For instance, STIP1 takes part in delivery of steroid hormone 
receptor clients, while CDC37 is attributed to delivery of protein kinase clients to 
HSP90. The co-chaperons TAH1 and PIH1 are essential for delivering nascent forms 
of various ribonucleoproteins that participate in many different processes including 
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DNA replication, ribosome synthesis and telomerase maintenance (Boulon et al., 
2008). Additionally, these co-chaperons are associated with the chromatine-
remodelling factors RVB1 and RVB2, elucidating the role of HSP90 in the epigenetic 
modulation of transcription.  
 
1.11.3. Client proteins of HSP90 
There are reported more than 200 client proteins for HSP90 (Figure 9). The clients 
include: transcription factors, chromatin remodeling factors, protein kinases, 
ribonucleoproteins, steroid hormone receptors, kinetochore complex as well as 
structural proteins, for instance actin and tubulin (Whitesell and Lindquist, 2005). 
HSP90 associates with core co-chaperones such as p23 (also known as PTGES3 and 
as Sba1 in yeast), HSC70 and HSP90-organizing protein (HOP; also known as p60 
and STI1) and the HSP40–HSP70 chaperone system; orange) and other co-
chaperones (green). Adaptor co-chaperones such as Cdc37 and SGT1 associate with 
a limited number of proteins or protein domains (blue). However, for most HSP90 
clients, it is not known which co-chaperones, if any, are associated in the complex 
(marked by question mark). 
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Figure 9. HSP90 regulates diverse cellular processes through its interaction with client proteins 
(Taipale et al., 2010).  
 
1.11.4. Heat shock protein 90 (HSP90) in cancer 
HSP90 is a master regulator in cancer biology due to the broad spectrum of oncogenic 
client proteins. Cancer cells proliferate faster and need HSP90 rigorously, while healthy 
cells rely on HSP90 modestly to maintain physiological functions. This situation is 
termed ‘HSP90 addiction’ (Miyata et al., 2012). The higher number of HSP90-
dependent proteins may accumulate in cancer cells, therefore HSP90 is more occupied 
with its clients proteins in cancer cells. Further, the difference in structure and/or post-
translational modifications of HSP90-clients can be one of the reasons why the cancer 
cells are more sensitive to HSP90 inhibition (Kamal et al., 2003). More importantly, 
highly-unstable mutant oncogenic proteins, which arise during tumor transformation, 
are stabilized by HSP90 and its co-chaperons. HSP90 and its association with cancer 
pathobiology are described below. 
 
1.11.4.1. Hypoxia inducible factor (HIF) 
HIF is probably one of the most potent proangiogenic proteins regulated by Hsp90. It 
has been shown that both the HIF-1a and HIF-2a subunits are client proteins for 
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HSP90 and the chaperone activity is important for HIF stability and function (Milkiewicz 
et al., 2007; Dörthe M Katschinski, 2004). HIF overexpression correlates with highly 
vascularized tumors, resistance to chemo- and radiotherapy, and overall poor 
prognosis (Rankin and Giaccia, 2008).  
 
1.11.4.2.Vascular endothelial growth factor/vascular endothelial growth factor 
receptors (VEGF/VEGFRs) 
Vascular endothelial growth factor (VEGF) are involved in organizing new blood 
vessels growth during embryonic and postnatal development. Receptors for VEGF 
(VEGFR1 and VEGFR2) are Hsp90-clients, and their stability and functions rely on the 
Hsp90 chaperone machinery. The inhibition of HSP90 can leads to tumor regression 
and suppression of metastasis (Laederich et al., 2011). 
 
1.11.4.3. Epidermal growth factor receptor (EGFR/HER2) 
The receptor tyrosine kinase HER-2 (also known as ErbB-2) is a protein whose stability 
depends on HSP90 function (Zhou et al., 2003). HER-2 is a ligandless receptor and the 
preferred heterodimerization partner for ligand-bound epidermal growth factor receptor 
family members HER-1, HER-3, and HER-4 (Citri et al., 2003). Moreover, 
overexpression of the HER-2 receptor is associated with increased progression and 
metastasis in human breast cancer (Sidera et al., 2008). 
 
1.11.4.4.Telomerases 
The elongation of telomeres by the telomerase is a crucial step for cancer cells to 
achieve immortalization. Telomerase is overexpressed in the majority of human cancer 
cells and consists of a reverse transcriptase catalytic subunit hTERT. HSP90 and its 
co-chaperone p23 were identified as hTERT-binding partners, and they contribute to 
the formation of functional telomerase complexes in cells. (DeZwaan et al., 2009). 
 
1.11.4.5. p53 
p53 tumor suppressor protein is a crucial transcription factor that regulates cell cycle 
and initiates apoptosis. Inactive mutants are found in more than 50% of human cancers 
(Brady and Attardi, 2010). Many studies have shown that HSP90 interacts with mutant 
p53 and inhibition of HSP90 promotes its degradation (Blagosklonny et al., 1996),    
(Nagata et al., 1999). Interestingly, opposing effects on wild-type and mutant p53 has 
been observed with HSP90 inhibition (Lin et al., 2008).  
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1.11.5. HSP90 in other diseases 
Aside from the focus on HSP90 in cancer biology, HSP90 has gained increasing 
attention on neurodegenerative disease. It leads to abnormal tau phosphorylation by 
stabilizing p53 or directly interacting with mutated form of tau protein. Thus it influences 
the accumulation of toxic tau aggregates in tauopathy like Alzheimer’s disease and 
frontotemporal dementia (FTD) (Dickey et al., 2007).  
HSP90 is also a key stress protein involved in both the interaction with and response to 
microbes and viruses. For example, HSP90 plays a key role in folding of basic viral 
proteins (Geller et al., 2007), therefore HSP90 inhibition makes possible to block the 
replication of poliovirus and paramyxovirus (Geller et al., 2013). 
 
1.11.6. Therapeutic implications of HSP90 inhibitors 
1.11.6.1. Inhibition of N-terminal domain 
The first identified inhibitors were the natural benzoquinone ansamycin geldanamycin 
(GM) and the macrolactone radicicol (RD) extracted in 1970 and 1953, respectively. 
Both inhibitors bind to the N-terminal ATP binding pocket of HSP90 which results in 
selective inhibition of ATP binding and hydrolysis of HSP90 (Xu et al., 2002). However, 
geldanamycin and radicicol have some pharmacological disadvantages like toxicity and 
limited solubility, they provided the chemical basis for drug development. The 
semisynthetic GM analogues were developed: 17-allylamino-17-
demethoxygeldanamycin (17-AAG, tanespimycin, KOS-953), a carbon-17 substituted 
derivate which is less toxic and shows similar anti-proliferative effects (Eckl and 
Richter, 2013) (Figure 10). In phase I studies, 17-AAG presented clinical activity in 
various malignancies such as HER+, trastuzumab-refractory breast cancer with side 
effects (diarrhea, fatigue, headache or neuropathy) manageable with supportive 
medications.  However, despite the promising results in the treatment of breast cancer, 
different animal model studies consistent with the clinical data showed that there is 
cytostatic arrest and growth inhibition rather than tumor regression (Sawai et al., 2008). 
Another limitation of 17-AAG is the requirement for reductive metabolism of the 
benzoquinone by NADPH quinone oxidoreductase 1 (NQO1). This reaction enhances 
the drug’s inhibitory potency but it can also leads to liver toxicity (Gaspar et al., 2009). 
17-DMAG (alvespimycin), another geldanamycin analog which is water soluble, 
displays better pharmacokinetic properties and higher oral (Egorin et al., 1998). In 
addition, it is less sensitive to and dependent on NQO1, therefore presents low toxicity. 
The recent phase I studies with intravenous 17-DMAG showed response in patients 
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with advanced solid cancers such as castrate-refractory prostate cancer and 
melanoma (Pacey et al., 2011).  
 
 
 
 
 
Figure 10. The structure  of geldanamycin, 17-AAG and 17-DMAG (Li et al., 2009). 
 
1.11.6.2. Inhibition of C-terminal domain 
Coumarin antibiotics, such as novobiocin, clorobiocin and coumermycin A1 target C 
domain of HSP90. However, they are all excluded from further evaluation in clinical 
studies due to the low affinity to HSP90 compared with their affinity to topoisomerases 
type II (Trepel et al., 2010). Recently, some improving of these compounds has been 
attained. One of them, such as F-4, presents similar efficacy as 17-AAG in inducing 
apoptosis in PC-3 and LNCaP prostate cancer cell lines (Matthews et al., 2010). 
Another novobiocin derivative termed KU135 inhibits proliferation and induced 
apoptosis of Jurkat T cell (leukaemia lymphocytes) more potently than 17-AAG 
(Shelton et al., 2009).  
 
1.11.6.3. Disruption of co-chaperone/ HSP90 interactions 
Besides the drugs which target N and C domain, attempts have been made to develop 
new inhibitors targeting hydrophobic protein-protein interaction surfaces of HSP90. 
Recent molecular docking studies and molecular dynamic simulations showed natural 
product celastrol disrupts the interaction of HSP90 with its co-chaperone CDC37 and 
destabilizes various HSP90 clients kinases against pancreatic cancer cells (Zhang et 
al., 2008). However, these strategies remain highly challenging, considering that 
nowadays little is known about the structural and biochemical interactions between 
HSP90 and its clients.  
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2. AIMS OF THE STUDY 
HSP90 is a highly conserved chaperone protein and is essential for stabilization or 
degradation of many signaling proteins. HSP90 is centrally involved in the pathobiology 
of cancer and HSP90 inhibitors have been widely investigated in preclinical and clinical 
studies against cancer. Recent evidence shows that HSP90 promotes epithelial-
mesenchymal transition (EMT) of cancer cells and TGF-β1 signaling via the stabilizing 
of the TGF-β receptors, however little is known about the role of HSP90 in IPF.  
The purpose of the present study is to discover the role of HSP90 in lung fibroblast 
activation, particularly with regard to TGF-β1-induced profibrotic phenotype, and to 
determine the effects of HSP90 inhibitor on bleomycin-induced pulmonary fibrosis in 
mice as well as to offer new selective theraphy targets for IPF. 
In this study, a series of study were undertaken as follows: 
 
1. Confirm differential HSP90 expression by real-time PCR, western blot and 
immunohistochemistry: 
a. in human lung and interstitial lung fibroblasts (ILFBs) from donor and patients 
with IPF  
b. in mouse lung and ILFBs from healthy mice and bleomycin-administrated mice  
 
2. Determine the in vitro effects of 17-AAG on: 
a. TGF-β-induced fibroblast activation demonstrated by western blot of α-SMA 
b. TGF-β-induced fibroblast extracellular matrix (ECM) production carried out by 
Sircol Soluble Collagen assay and western blot of collagen I and fibronectin 
c. FCS-induced fibroblast migration performed by transwell assay and scratch 
assay 
 
3. Characterize TGF-β RII as a target protein and SMAD2 and SMAD3 as downstream 
molecules of HSP90 by western blot. 
 
4. Use the MG-132 inhibitor to prove that 17-AAG block TGF-β/Smad signaling in IFBs 
by diminishing TGF-βRs levels by proteasome degradadion. 
 
5. Perform co-immunoprecipitation to demonstrate the direct interactions between 
HSP90β and TGF-β RII. 
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6. Investigate the in vitro effects of HSP90 inhibition on epithelial-mesenchyman 
transition (EMT) revealed by western blot and immunofluorescence staining of 
mesenchymal and epithelial markers. 
 
7.  Evaluate the in vivo effects of 17-DMAG on attenuation of pulmonary fibrosis using 
the established bleomycin-induced IPF mouse model. The following experiements were 
investigated: 
a. inflammatory cell composition in bronchoalveolar lavage fluid (BALF) 
b. respiratory function (lung compliance and tissue damping) by FlexiVent 
c. histological assessment including Ashcroft fibrosis scoring and collagen 
deposition 
d. activity of  matrix metalloproteases (MMPs) measured by in vivo fluorescence 
molecular tomography (FMT) in combined with micro-computed tomography 
(µCT) 
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3. MATERIALS AND METHODS 
3.1. Materials 
3.1.1. Chemicals, reagents, kits 
Company Product 
17-AAG inhibitor Selleck, USA 
17-DMAG inhibitor LC Laboratories, USA 
2-propanol Sigma- Aldrich, Germany 
Acetic acid Sigma- Aldrich, Germany 
Acrylamid Roth, Germany 
Ammonium persulfate (APS) Sigma- Aldrich, USA 
Ampicillin sodium salt Sigma, USA 
Bis(sulfosuccinimidyl)suberate (BS3) Thermo Scientific, USA  
Bleomycin Sigma-Aldrich, USA 
Bovine serum albumin powder Serva, Germany
Bovine serum albumin (2 mg/ml)  Bio-Rad, USA 
Bromophenol blue  Merck, Germany 
Cell proliferation ELISA, BrdU  Roche, USA 
Citric acid monohydrate  Sigma, Germany 
Collagenase type IV  Sigma-Aldrich, USA 
Crystal violet solution 2.3% w/v  Sigma-Aldrich, USA 
DAPI  Dakocytomation, USA 
DC™Protein Assay  Bio-Rad, USA 
DEPC water  Roth, Germany
Disodium phosphate (Na2HPO4 x H2O)  Roth, Germany 
Dithiothreitol (DTT)  Sigma-Aldrich, USA
Dynabeads Protein G  Life Technologies, USA 
Enhanced chemiluminescence (ECL) kit Amersham, USA
Eosin-Y alcoholic Thermo Scientific, UK 
Ethanol 70%  SAV LP, Germany 
Ethanol 96% Otto Fischhar, Germany 
Ethanol 99.9% Berkel AHK, Germany 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich, USA 
Formaldehyde 3.5-3.7%  Fischer, Germany 
Giemsa Merck, Germany
Glycerol Sigma-Aldrich, USA
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Hematoxilin Haemalaun nach Mayer Waldeck, Germany 
iScript cDNA synthesis kit Bio-Rad, USA 
Isoflurane  Baxter, UK
iTaqSYBR Green Supermix Bio-Rad, USA
May-Gruenwald  Merck, Germany 
Methanol  Sigma-Aldrich, USA 
MMPSense™ 680                                                               Perkin Elmer, USA                   
MG-132 inhibitor     Calbiochem, USA
Monopotassium phosphate (KH2PO4) Roth, Germany
Non-fat milk  Roth, German
Paraformaldehyde Sigma-Aldrich, USA 
Paraplast® Plus paraffin embedding 
medium  
Sigma-Aldrich, USA
Pertex® mounting medium  Medite, Germany
Picric acid solution 1.2%  AppliChem, Germany
Positively charged glass slides Langenbrinck, Germany 
Potassium chloride (KCl) Sigma-Aldrich, USA 
Precision Plus Protein Standards  Bio-Rad, USA 
RIPA buffer  Santa Cruz, USA 
S.O.C solution  Invitrogen, USA 
Saline (NaCl 0.9%)  B. Braun, Germany
SDS Solution, 10% w/v Promega, USA 
SIRCOL collagen assay  Biocolor Ltd., UK 
Sirius red F3B  Niepoetter,  Labortechnik
Sodium chloride (NaCl)  Sigma-Aldrich, USA  
Sodium citrate tribasic dehydrate  Sigma, Germany 
Tetramethylethylenediamine (TEMED)  Sigma-Aldrich, USA
TGF-β1 R&D System, USA 
Tissue-Tek® O.C.T™ Compound Sakura, Japan
Tris-HCl 0.5 M, pH 6.8  Amresco SOLON, USA  
Tris-HCl 1.5 M, pH 8.8  Amresco SOLON, USA  
Tris-HCl  Roth, Germany 
Triton-X100  Sigma-Aldrich, USA 
TRIzol® Reagent  Life Technologies, USA 
Trypsin 2.5%  Invitrogen, USA
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Tween®20  Sigma-Aldrich, USA 
UltraPure water Cayman Europe, Estonia 
Xylol (isomere) >98% pure, for histology  Roth, Germany
ZytoChem-Plus AP Kit, Broad Spectrum  Zytomed Systems
β-Mercaptoethanol Sigma-Aldrich, USA
3.1.2. Cell culture medium 
MCDBI-131 medium, HBSS (Hank´s buffered saline solution) PBS, L-glutamine, 
penicillin/streptomycin and Trypsin/EDTA are all purchased from PAN (Germany). Fetal 
calf serum (FCS) is from Biowest (Germany) and insulin from Sigma-Aldrich (USA). 
Basic fibroblast growth factor (bFGF) and human epidermal growth factor (EGF) are 
purchased from Peprotech (USA). The rest including DMEM/F12 medium, Opti-MEM 
medium, MEM vitamin solution and MEM non-essential amino acids solution are all 
from Gibco, Life Technologies (USA).  
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3.1.3. Antibodies 
Table 2.  Primary antibodies 
Antibody (catalog number) Host Dilution Company 
Alpha smooth muscle actin (α-
SMA), (ab5694) 
rabbit polyclonal 
antibody 
1:1000 
1:100 
Abcam, UK 
Beta- actin (β-actin), (ab6276) mouse monoclonal 
antibody 
1:4000 Abcam, UK 
Collagen type I, (T40777R) rabbit monoclonal 
antibody 
1:1000 Meridian, USA 
E-cadherin, (07-697) rabbit polyclonal 
antibody 
1:1000 Millipore, USA 
E-cadherin, (610181) mouse monoclonal 
antibody 
1:100 BD Biosciences, USA 
Fibronectin, (F0916) mouse monoclonal 
antibody 
1:1000 
1:200 
Sigma-Aldrich, USA 
HSP90α, (ADI-SPS-771) rabbit polyclonal 
antibody 
1:1000 
1.100 
Enzo Life Sciences, 
USA 
Hsp90β, (ab53497) rabbit polyclonal 
antibody 
1:100 Abcam, UK 
HSP90β, (ADI-SPA-844) rabbit polyclonal 
antibody 
1:1000 
Enzo Life Sciences, 
USA 
IgG control, (NB810-56910) rabbit polyclonal 
antibody 
1:75 Acris, USA 
IgG control, (sc-2027) rabbit polyclonal 
antibody 
2 µg/ 0.75 
mg lysate 
Santa Cruz, USA 
SMAD2 (pSer465, pSer467), 
NB200-629 
rabbit polyclonal 
antibody 
1:1000 Novus Biologicals, UK 
SMAD2, (5339) rabbit monoclonal 
antibody 
1:1000 Cell Signaling, USA 
SMAD3 (pSer423, pSer425), 
(PS1023) 
rabbit monoclonal 
antibody 
1:1000 Calbiochem, USA 
SMAD3, (9523S) rabbit monoclonal 
antibody 
1:1000 Cell Signaling, USA 
TGF-β receptor I, (3712) rabbit polyclonal 
antibody 
1:1000 Cell Signaling, USA 
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Table 2. (continued) 
TGF-β receptor II, (3713) rabbit polyclonal 
antibody 
1:1000 Cell Signaling, USA 
TGF-β receptor II, (sc-400) rabbit polyclonal 
antibody 
1:1000 
2 µg/ 0.75 
mg lysate 
Santa Cruz, USA 
TTF1, (ab76013) rabbit monoclonal 
antibody 
1:100 Abcam, UK 
 
HRP-conjugated secondary antibody 
Rabbit anti-mouse IgG (1:40000), Sigma-Aldrich, USA 
Goat anti-rabbit IgG (1:50000) Pierce, USA 
 
Fluor-conjugated secondary antibody 
Goat anti-mouse DyLight549 IgG (1:5000), Zytomed, Germany 
 
3.1.4. Primers 
Table 3. Primers for quantitative RT-PCR 
Gene  Primer Sequence 
HumaHSP90A class A1 (HSP90AA1) Forward 5’ TGCCTTTTGCCTTAAGGTCTC 3’ 
Reverse 5’GAT TGG TGA CAT CTC CATGCT 3’ 
Human HSP90A class B1 (HSP90AB1) Forward 5’CTT GAC TGC CAA GTG GTCTTC 3’ 
Reverse 5’GAT CGA AGA TGT GGGTTCAGA 3’ 
Human HSP90B1 Forward 5’CCC GTC CTA GAG TGT TTCCTC 3’ 
Reverse 5’ CCA GTT TGG TGT CGGTTTCTA 3’ 
Mouse HSP90A class A1 (HSP90AA1) Forward 5’ GAC TCC CAG GCA TAC TGC TC 3’ 
Reverse 5’ AAT AAC CTT GGC ACC ATT GC 3’ 
Mouse HSP90A class B1 (HSP90AB1) Forward 5’AGG GTT GAT CTC CAG GTGTTT 3’ 
Reverse 5’TGG GAA CCA TTG CTA AGTCTG 3’ 
Human HSP90B1 Forward 5’TCC ACG ACC TAG TGT GTT TCC 3’ 
Reverse 5’ CCA GTT TGG TGT CGG TTT TTA3’ 
 
   
MATERIALS AND METHODS 
40 
 
3.1.5. Equipments 
Equipment Company 
Balance 1.0-3000g RP 3000 August Sauter, Switzerland 
Balance PCB 200-2 Precision Kern, Germany 
Balance XS205  Mettler Toledo, Switzerland
BioDoc Analyzer Biometra, USA
Cell culture incubator  Hera Cell Heraeus, 
Centrifuge Roranta 460R Hettich, Germany
Cooling plate for paraffin-embedding 
EG1150C 
Leica, Germany 
Cytospin™ 4 Cytocentrifuge  Thermo Scientific, USA
Electrophoresis chamber  Bio-Rad, USA
FlexiVent  SCIREQ, Canada 
Fluorescence Molecular Tomography 2000  
Freezer (+4°C, -20 °C, -80 °C)  
Perkin Elmer 
Bosch, Germany 
Incubator hood TH 15  Edmund Buehler 
Infinite® 200 microplate reader  Tecan, Switzerland 
Inolab PH meter  WTW, Germany 
Light microscope DM IL  Leica, Germany 
Light and fluorescence microscope 
DM6000 B  
Leica, Germany  
Live imaging microscope DMI6000 B Leica, Germany
Material test chamber with mechanical 
convection F53  
Binder, Germany
Microtome RM2165  Leica, Germany 
Mounting bath HI1210  Leica, Germany 
Mounting heating plate HI1220 Leica, Germany 
Multifuge centrifuge Heraeus, Germany 
Mx3000P qPCR System  Stratagene, USA
NanoZoomer 
Paraffin-embedding system EG1140H 
Hamamatsu, Germany 
Leica, Germany 
Pipetboy and pipettes  Eppendorf, USA
Power supply  Bio-Rad, USA 
Precellys®24 homogenizer  Bertin Technologies, France
Rotator Staurt®SB3  Bibby Scientific, U.K. 
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Shaker  
SkyScan 1178 high-throughput micro-CT 
Bruker, Belgium   
Biometra, USA
Tissue processor TP1050  
Tissue processor ASP 300S  
Thermocycler T3000  
Leica, Germany 
Leica, Germany 
Biometra, USA 
Vortex machine  VWR, Germany 
Water bath for cell culture HLC, Germany
Water bath for tubes Medingen, Germany
Western blot unit Bio-Rad, USA
3.1.5. Other materials 
Material Company 
6-well, 24-well, 96-well microplate  Corning, USA 
AGFA cronex 5 medical X-ray film  AGFA, Belgium
Chromatography column  Bio-Rad, USA 
Cover glass 60 x 24 (0.13-0.18 mm)  Langenbrinck, Germany
Falcon tubes                                   BD Biosciences, USA 
Film cassettes  Kodak, USA 
Filter tips (10, 100, 1000µl)  
Gel blotting paper  
Glass pipettes, cell culture dishes, plates 
Nerbe plus, Germany 
Whatman, USA 
Sarstedt, Germany 
Glass slides Super Frost® Plus R. Langenbrinck, Germany 
Needles 26-20G (0.45-0.9mm)      
Microlance™ 3 BD  
Drogheda, Ireland 
Nitrocellulose membrane  Bio-Rad, USA 
Osmotic minipump (2 mL)  Durect Corparation, USA 
Precellys bead mill sample tube  Bertin Technologies, France 
Radiographic films hypersensitive  Amersham, USA 
Radiographic films  Santa Cruz, USA 
Scalpels Feather, Japan 
Scissors, forceps, clamps  Fine Scientific Instruments
Shandon™ Single Cytofunnel™ with 
Cytoclips™ and White Filter Shandon 
Thermo Scientific, USA   
Shandon™ Single Cytoslides™ Thermo Scientific, USA  
Syringes 1, 2, 5, 10, 25 ml  B. Braun, Germany 
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Tips (10, 100, 1000µl)  Eppendorf, USA 
Tissue culture chamber slide  BD Falcon, USA 
Transwell permeable support  Corning, USA 
 
3.1.6. Softwares 
Software Company
FlexiWare 7.0  SCIREQ, Canada 
i-Control  Tecan, Austria 
Leica Application Suite Advanced 
Fluorescence (LAS AF) Microscope 
Software 
Leica, Germany 
 
Leica QWin imaging software Leica, Germany                                                                                                                             
Magellan v.6.3  Tecan, Austria 
MS® Excel and Word 2013  Microsoft, USA 
MxPro™ QPCR software   Agilent Technologies, USA
Prism® v6.05    GraphPad Software, USA 
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3.2. Methods 
3.2.1. Patients 
Human lung tissue was obtained from three donors and three patients suffering from 
IPF who underwent lung transplantation at the Department of Thoracic Surgery, 
University of Vienna Hospital in Austria. The study protocol for human tissue donation 
was approved by the Ethics Committee of the Justus-Liebig-University School of 
Medicine (No. 31/93, 29/01, and No. 111/08: European IPF Registry), and written 
informed consent was obtained from each individual patient or the patient’s next of kin. 
The material was prepared accordingly to the further assessment.  
 
3.2.1.1. Human interstitial lung fibroblasts (hILFBs) 
Human interstitial lung fibroblasts were isolated, as described previously (Jablonska et 
al., 2010). Lung specimens of the pulmonary parenchyma were chopped into <1-mm3 
pieces. The minced pieces were washed twice with PBS and then plated in 100-mm 
dishes. After fibroblasts have grown out from the tissues, the slices were removed by 
aspiration, and the cells were allowed to reach confluence. Confluent fibroblasts were 
then passaged by trypsin treatment and used for the experiments between passages 3 
and 4. After the second passage, fibroblasts were frozen in 10% DMSO, 10% FCS and 
DMEM. The experiments were started from frozen aliquots of human ILFBs.  
3.2.1.2. RNA and protein  
Human lung tissue was obtained from three donors and four IPF patients that 
underwent lung transplantation in Medical University of Vienna (Vienna, Austria) and 
had a confirmed UIP histological pattern. Pieces of lung tissue were snap-frozen 
immediately upon lung excision and used for mRNA and protein extraction. 
 
3.2.1.3. Histology examination 
At the surgical theatre, peripheral lung tissue samples (of explanted IPF-) were 
immeresed in 4% (PFA, pH 7.0) immediately after transplantation. The remaining lung 
tissue was flushed, cooled down to +4°C, and sent (together with the formalin-fixed lung 
tissue samples) immediately to Giessen. There the lung lobes were prepared according 
to a predefined algorithm; and additional lung tissues samples from subpleural and hilar 
regions were placed in 4% PFA. Next, the lung was processed according to lung tissue 
preparation protocol described in further section.  
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3.2.2. Animals 
Adult male 12-week-old C57BL/6 mice in body weight between 20-25 g were obtained 
from Charles River Laboratories. Both the University Animal Care Committee and the 
Federal Authorities for Animal Research of the Regierungspraesidium Giessen 
(Hessen, Germany) approved the study protocol (GI20/10, number 59/2012). Animals 
were housed under room temperature and 12/12-hour light/dark cycle with free access 
to food and water. 
 
3.2.3. Bleomycin administration 
At day 0 mice were anesthetized with 5% isoflurane following orotracheal instillation of 
bleomycin at the dose of 3.5 units/kg mouse body weight or sterile saline (0.9% NaCl). 
The animal was fixed in a vertical position under a binocular.  During instillation nose of 
a mouse was kept pinched to ensure that during inspiration bleomycin or saline 
solutions were inhaled and distributed throughout the lung. Bleomycin was dissolved in 
sterile saline to achieve the required dose. 
 
3.2.4. Experimental groups 
Animals were divided in the following four groups. Group I served as normal control 
mice, which received instillation of sterile saline at day 0 and was given vehicle alone 
(saline); Group II served as bleomycin-induced pulmonary fibrosis mice, which received 
instillation of bleomycin at day 0 and were given vehicle; Group III and Group IV served 
as the treatment groups where mice received bleomycin at day 0 and were treated 
every second day from day 8 to day 21 with 10 mg/kg or 25 mg/kg 17-DMAG (LC 
Laboratories), respectively. 17-DMAG was prepared freshly in saline at 2 or 5 mg/ml 
and administrated per os via gavage needle, all in the same manner. Survival of each 
group was expressed as percentage of mice alive at the specific time points of the 
experiment.  
 
3.2.5. Measurement of lung function 
At day 21 after bleomycin instillation, respiratory function measurement was performed 
using a computer-controlled piston ventilator FlexiVent. This system introduces the 
forces oscillation technique (FOT) which is a powerful tool allowing the experimental 
performance of lung function in mice. It ensures measurements of respiratory system 
mechanics through the analysis of volume and pressure signals acquired in reaction to 
predefined, small amplitude, oscillatory airflow waveforms. Lung function 
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measurements were performed in dead mice. After system and cannula calibration, 
mice ware placed on flexiVent system followed by the insertion of tracheal cannula. 
Further, the deep inflammation was executed to recruit closed lung areas and 
standardize lung volume history and the pressure of 30 cmH2O over a 3 second period 
without excessive volume displacement.  Three single-compartment perturbations and 
three constant-phase perturbation were obtained. The averages of these three 
measurements were determined for each animal and averaged for each experimental 
group. Lung function parameters were automatically calculated by the software, by 
fitting pressure and volume data to the single compartment model measuring dynamic 
compliance (C) with the Snapshot-150 perturbation and measuring the constant-phase 
and tissue damping (G) with the QuickPrime-3 perturbation, respectively. Dynamic 
compliance captures the ease with which the lung can be extended. Tissue damping is 
closely related to tissue resistance and reflects the energy dissipation in the lung. Only 
measurements with coefficient of determination (COD) ≥0.9 were used for further 
analysis (McGovern et al., 2013).  
 
3.2.6. Bronchoalveolar lavage fluid (BALF) cell count 
After respiratory function measurement, lungs were lavaged three times with 0.3 ml of 
ice cold saline and all aliquots were pooled for each lung. Further, BAL fluid was 
centrifuged and cell pellet was resuspended in 1 ml of saline. Cells in constant volume 
of 0.2 ml of PBS were deposited in a cytospin funnel and transferred to a glass slide 
with Shandon Cytospin-3® centrifuge at 500 rpm for 5 minutes followed by drying. 
Slides were stained with May Gruenwald-Giemsa using the following protocol: 
 
         Table 4. Gruenwald-Giemsa staining protocol 
Step duration Duration (min) 
May Gruenwald 10 min 
Washing with distilled water 1 min 
Giemsa 5 min 
Washing with distilled water 1 min 
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Numbers of macrophages, neutrophils and lymphocytes were determined by counting 
of 100 cells under the Leica light microscope DM6000 B. Different cell count was 
expressed in %. 
 
3.2.7. Lung tissue harvest and preparation 
After respiratory measurement, whole lungs were flushed through the pulmonary artery 
with saline due to remove red cells. Three right lobes were snap frozen in liquid 
nitrogen and stored in -80º C for molecular biology assessment, while left lobe was 
placed in OCT mounting medium, snap frozen in liquid nitrogen and stored in -80º C for 
cryosections. Further, one left lobe was perfused under 22 cmH2O pressure through 
the pulmonary artery with 3.5-3.7 % of formalin and immersed in formalin for 24 hours.  
Formalin-fixed lung tissue samples were transferred to embedding cassettes and 
stored in phosphate-buffered saline (PBS). The dehydration was performed overnight 
in Leica ASP 300S tissue processor. Next day, the lung tissues were embedded in 
65°C warmed paraffin with the usage of a heated Leica paraffin embedding module. 
Then the paraffin-embedded lung tissues were cooled down for hardening on a Leica 
cooling plate followed by sectioning into 3 µm-thickness on Leica fully-automated 
rotation-microtome, and mounted on positively charged glass slides. Finally, lung tissue 
sections were allowed to dry on Leica heating plate at 40°C and incubated at 37° C (for 
12 hours) in a drying oven. 
 
3.2.8. Fibrosis score and collagen quantification in lung tissue sections 
To examine fibrosis morphological changes, lung tissue sections were stained with 
hematoxylin and eosin according to the protocol below. Next, fibrosis scores were 
quantified according to a numerical scale as described by Ashcroft and colleagues 
(Ashcroft et al., 1988) with slight modifications: 0- healthy lungs were referred to score 
“0”; whereas score “6” represented the most severe degree of fibrosis. Main scores are 
0, 2, 4, 6. 0- normal lung, 2- minimal fibrosis (septae thickening without distortion of 
lung architecture), 4- substantial fibrosis (fibroblastic foci, distortion of lung 
architecture), 6- maximal fibrosis (scar formation). There also intermediate scores: 1, 3, 
5 which are used in case weakly expressed scores 2, 4, 6.                        
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                               Table 5. Hematoxylin and eosin staining 
Step duration Duration, min 
3 x Xylol 10 
Ethanol 99.6% 5 
Ethanol 99.6% 5 
Ethanol 96% 5 
Ethanol 70% 5 
Distilled water 2 
Haemalaun nach Mayer, acidic 20 
Tap water 5 
Ethanol 96% 1 
Eosin-Y alcoholic 4 
Distilled water rinse 
Ethanol 96% 2 
Ethanol 96% 2 
Ethanol 99.6% 5 
Isopropanol 99.8% 5 
3 x Xylol  5 
 
Collagen deposition on slides, expressed in %, was assessed by Sirius Red staining 
according to the protocol below. The sections were examined under a Leica DM 600B 
microscopy using Leica QWin imaging software. 0.1% picro Sirius red (0.1g Sirius Red 
in 100 ml picric acid). 
 
 
 
 
 
 
 
  
MATERIALS AND METHODS 
48 
 
                             Table 6. Sirius Red staining 
Step duration Duration, min 
Incubation at 58°C 60 
3 x Xylol 10 
Ethanol 99.6% 5 
Ethanol 99.6% 5 
Ethanol 96% 5 
Ethanol 70% 5 
Deionized water shortly 
0.1% picro Sirius red 60 
Acidifier water (1% glacial acetic acid) 2   
Acidifier water (1% glacial acetic acid) 2  
Acidifier water (1% glacial acetic acid) 2 
Dip in deionized water and shake shortly 
Ethanol 70% 5 
Ethanol 96% 5 
Ethanol 99.6% 5 
2 x Xylol 2 
 
3.2.9. Fluorescence molecular tomography and micro computed tomography 
(FMT- µCT) 
FMT system (FMT2000) is a small-animal fluorescence in vivo imaging system for 
murine preclinical research use. It is designed to provide calibrated quantitative 
tomographic images and data of fluorescence signal within biological tissue (in lungs) 
throughout the depth of the subject. This two channel instrument operates on two near-
infrared channels excited at 670 nm and 746 nm, and emitting at 700 nm and 750 nm 
respectively.  
The SkyScan 1178 is an ultra-fast micro-CT system for high throughput in vivo 
scanning of small laboratory animals. During scanning the source-camera assembly 
turns around the object 360oC whole body scan, which remains statically in the carbon-
composite bed. The instrument is supplied with integrated physiological monitoring for 
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in vivo small animal scanning, including color real-time imaging of the animal during 
investigation, gating from breathing, body temperature measurement, heart beats and 
stabilization.  
 
             Figure 11. PerkinElmer FMT and 3D tomographic imaging 
 
Mice were shaved and depilated to remove all hair to avoid absorb autofluorescence.  
Further, animals were anesthetized with isoflurane and fixed into a portable animal 
imaging cassette that lightly compressed the anesthetized mouse between optically 
translucent windows thereby preventing the motion during FMT and CT imaging. The 
animal holder with the anesthetized mouse was put to µCT (micro computed 
tomography), followed by transfer of the holder to FMT system. 
The MMP activatable fluorescent probe, MMPSense680, was administrated via tail vein 
24 hours before the FMT measurement. MMPSense680 probes (~ 450kDa) is optically 
quenched in its native form  and becomes highly fluorescent with an excitation at 670 
nm and emission at 700 nm and activated by Matrix Metalloproteinases MMP-2, -3, -9 
and -13 (http://www.perkinelmer.com/catalog/category/id/in vivo imaging). In vivo MMP 
activity in mice lung was monitored by quantitative FMT at day 21 after bleomycin 
administration in sham and bleomycin-challenged mice (Bleo) in the absence or 
presence of 17-DMAG (10 mg/kg or 25 mg/kg, every two days from day 8 to day 21). 
Micro CT was performed for organ and accurate signal localization.  
After setting regions of interest on the basis of the anatomic µCT data, MMPSense680 
concentration in the lungs were determined by Analyze11.0, a software package 
developed by the Biomedical Imaging Resource (BIR) at Mayo Clinic for scanning, 
reconstruction and calculation of three-dimensional fluorochrome concentration and 
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distribution of MMPSense680. The FMT2000 TrueQuant software was used for the 
calculation of the MMP concentration (pmol). 
 
3.2.10. Mouse interstitial lung fibroblasts (mILFBs) isolation 
The tip of right ventricle was cut and the needle was stuck into the left ventricle close to 
the pulmonary artery. The lungs were perfused with saline until they became white. 
Then lungs were washed with HBSS until blood is removed and minced into 1 to 2-
mm3 pieces. Lung pieces were incubated in 5 ml digestion buffer (0.3 mg/ml type IV 
collagenase and 0.5 mg/ml trypsin, in HBSS-Ca/Mg) in a shaker at 37°C for 1 hour, at 
each of six 10-minutes intervals, the lung pieces were pipetted through a 10 ml pipette 
for 10 times to dissociate the cells. The digestion buffer was passed through a 40 µm 
Nylon cell strainer into a 50 ml tube to get rid of the undigested lung tissue. Next, cells 
were centrifuged for 5 minutes under 800 rpm. At the end the cell pellet was 
suspended with 9 ml pre-balanced culture medium (DMEM/F12, 10% fetal calf serum, 
penicillin (10,000 U/100 ml), streptomycin (10,000 µg/100 ml), glutamine (29.2 mg/100 
ml) and seeded in the dish. After attachment for 2 hours and cells were refreshed with 
new medium after washing twice with PBS.  
 
3.2.11. Human interstitial lung fibroblasts (hILFBs) 
Human interstitial lung fibroblasts were obtained from three donors and three patients 
with idiopathic pulmonary fibrosis (IPF). Cells were cultured in MCDB-131 medium, 
supplemented with 5% fetal calf serum, penicillin (10,000 U/100 ml), streptomycin 
(10,000 µg/100 ml), glutamine (29.2 mg/100 ml), 5 µg/ml insulin, 2 ng/ml basic 
fibroblast growth factor (bFGF), 0.5ng/ml human epidermal growth factor (EGF) in 
humidified atmosphere of 95% air with 5% CO2 at 37°C. 
Human ILFBs were stimulated with recombinant TGF-β1 (10 ng/ml) for 24 hours 
(western blots and co-immunoprecipitation), 72 hours (Sircol collagen assay), and 16 
hours (transwell assay), in the absence or presence of 17-AAG (50 nM), following 24 
hours of serum-starvation. 
Human ILFBs were pretreated with 17-AAG (50 nM) in the absence or presence of 
MG-132 (30 µM) for 5 hours and then stimulated with TGF-β1 (10 ng/ml) (treatment 
with MG-132, proteasome degradation inhibitor).  
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3.2.12. Epithelial- mesenchymal transition of A549 cells 
A549 (human lung adenocarcinoma cell line) cells were seeded in DMEM/F12 medium, 
supplemented with 10% FCS, penicillin (10,000 U/100 ml), streptomycin 
(10,000 µg/100 ml), glutamine (2 mM), 1% MEM vitamins solution, 1% MEM 
nonessential amino acids in humidified atmosphere of 95% air with 5% CO2 at 37°C.  
After attachment, A549 cells were kept in medium with 1% FCS for 24 hours and 
cultured in medium with 5 ng/ml TGF-β1 and 1% FCS for 72 hours in the absence or 
presence of 50 nM 17-AAG. Further, the cell morphology was examined by light 
microscopy, and the expression of epithelial and mesenchymal markers was carried 
out by fluorescence microscope and western blots. 
 
3.2.13. Polymerase chain reaction (PCR) 
3.2.13.1. RNA isolation 
Total RNA from tissues or cells was extracted using Trizol according to the 
manufacturer's protocol. 50 mg lung tissue was mixed with 1 ml Trizol and 
homogenized by Precellys24 homogenizer, or 1×106 of ILFBs were collected in 1 ml 
Trizol. These lysates were kept for 5 minutes at RT to dissociate the RNA from histone 
proteins. After adding of 0.2 ml chloroform, the sample was vigorously mixed and 
centrifuged at 12000 rpm for 15 minutes at 4°C. Next, the clear upper layer was 
carefully transferred to a new tube and gently mixed with 0.5 ml of 2-propanol. After 10 
minutes the mixture was centrifuged at 12000 rpm at 4°C for 15 minutes and the RNA 
pellet was washed with 1 ml of 75% ethanol and dried with opened lid. Finally, RNA 
was dissolved in DEPC-water and stored at -80°C. The quality and concentration of 
RNA was measured by NanoDrop spectrophotometer. 
 
3.2.13.2. Reverse transcription- polymerase chain reaction (RT-PCR) 
cDNA was synthesized by RT-PCR using Bio-Rad iScript cDNA synthesis kit according 
to the manufacturer’s instructions. 1 µg RNA in 20 µl mastermix was prepared 
according to the protocol. The reverse transcription reactions were subjected to cDNA 
synthesis by firstly annealing at 25°C for 5 minutres and incubating at 42°C for 30 
minutes, followed by thermal inactivation of reverse transcriptase at 85°C for 5 minutes. 
The cDNA was stored at -20°C. 
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                             Table 7. Reverse transcription- PCR 
RT- PCR reaction component Volume per reaction 
RNA (0.1 µg/µl) 10 µl 
5x iScript reaction mix 4 µl 
iScript reverse transcriptase 1 ul 
 
3.2.13.3. Quantitive realtime- polymerase chain reaction (qRT-PCR) 
The intron-spanning primer pairs were designed using the Primer3 program and are 
shown in Table 3. Primers were cross checked to insure the specificity by blasting to 
the whole genome. The product size is within the range of 80 bp-150 bp. 
 
        Table 8. qRT- PCR reaction components 
qRT- PCR reaction component Volume per reaction Final concentration 
cDNA 2 µl 0.2 
Forward primer 10 µM 0.5 µl 0.2 µM 
Reverse primer 10 µM 0.5 µl 0.2 µM 
iTaq SYBR Green supermix with Rox 12.5 µl   
Nuclease-free water to a final volume 20 µl  
 
qRT- PCR was performed on a Mx3000P® QPCR system machine using SYBR® iTaq 
SYBR Green Supermix with Rox kit according to manufacturer’s instructions. The 
cDNA was omitted for the negative control. The annealing temperature for every gene 
was 59°C. By using the MxPro™ QPCR software, a dissociation curve was generated 
for each gene to ensure a single product amplification and the threshold cycle (Ct 
values) was determined for each gene. The mRNA changes between sham and 
bleomycin mice or between donor and IPF patients were calculated as ∆Ct (Ct 
reference - Ct target). The Ct value was normalized to the reference gene hypoxanthin-
phosphoribosyl-transferase (HPRT) obtained for the same cDNA sample. Each 
reaction was run in duplicate and repeated three times independently. 
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                             Table 9. qRT- PCR program 
qRT- PCR program Temperature Time Cycle 
Activation 95°C 10 min   1 
Denaturation 95°C 30 sec 
 40                     Annealing 58°C 30 sec 
Extension 72°C 30 sec 
Denaturating 95°C 1 min  
Dissociation curve 55-95°C indefinite   1 
Soak 4°C indefinite   1   
 
3.2.14. Western blotting 
3.2.14.1. Protein isolation 
Total protein was extracted in RIPA buffer (containing: 1x TBS, 1% Nonidet  P-40, 
0.1% SDS, 0.5% sodium deoxycholate, 0.004% sodium azide) according to 
manufacturer’s instructions. Proteinase inhibitor cocktail, sodium orthovanadate and 
PMSF were added to RIPA freshly before use. 100 mg lung tissue homogenized in 600 
µl RIPA or 2×106 hILFBs in 300 µl RIPA was centrifuged at 12000 rpm for 30 minutes 
at 4°C and the supernatants were kept at -80°C. 
 
                                  Table 10. RIPA buffer recipe 
Component of RIPA Final concentration 
RIPA buffer 1x 
Protease inhibitor cocktail 1x 
Sodium orthovanadate 1% 
PMSF 1% 
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3.2.14.2. Protein concentration measurement 
Protein concentration was determined with Bio-Rad DC protein assay according to 
manufacturer’s instructions. The assay is based on Lowry assay with slight 
modifications. There are two steps leading to color development: the reaction between 
protein and copper in an alkaline medium (Reagent A) and the subsequent reduction of 
Folin (Reagent B) reagent by the copper-treated protein (Bio-Rad Manual instructions). 
A series of bovine serum albumin (BSA) concentration: 0.25- 0.5- 1- 2 mg/ml were 
used as standard. The protein samples were pre-diluted into the range of the standard 
and the protein concentration of each sample was estimated in duplicate. After 
developing of color samples were measured at 750 nm using Tecan microplate reader. 
Final protein concentration was calculated with accompanying Magellan™ software.  
 
3.2.14.3. SDS-polyacrylamide (SDS-PAGE) gel electrophoresis 
Protein samples with equal concentration were mixed with 5× SDS gel loading buffer at 
a ratio of 4:1 (v/v) and denatured at 100°C for 5 minutes. Protein samples (10 µg for β-
actin; 30 µg for other antibodies) or dual protein marker were loaded in the lanes of 8% 
SDS-PAGE gel and run at 100-130V for 2 hours to separate. Buffers are listed below. 
 
                                 Table 11. 5×SDS gel-loading buffer recipe 
5×SDS gel-loading 
buffer component 
Final concentration 
Tris-HCl (2 M, pH 6.8) 375 mM 
SDS 10% (w/v) 
Glycerol 50% (v/v) 
β-Mercaptoethanol 12.5% (v/v) 
Bromophenol blue 0.02% (w/v) 
 
Polyacrylamide gels were prepared according to following procedure. The space 
between the glass plates was filled with 8%-resolving gel mixture. Next, 2- propanol 
was poured on top of this mixture until the gels polymerized. After 30 minutes, water 
from resolving gel was removed and 6% stacking gel solution was added. A comb was 
inserted and polymerization took 30 minutes. The protocols for SDS-PAGE gels are 
listed below. 
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                        Table 12. Running buffer components 
Running buffer component Final concentration 
Tris-HCl 25 mM 
Glycine 192 mM 
SDS 10% (w/v) 0.1% (w/v) 
 
                 Table 13. Resolving gel (8%) components 
Resolving gel (8%) component Volume Final concentration 
Tris-Cl (1.5 M, pH 8.9) 2.25 ml 375 mM 
Acrylamid 30% (w/v) 2.4 ml 10% (w/v) 
SDS 10% (w/v) 90 µl 0.1% (w/v) 
APS 10% (w/v) 45 µl 0.05% (w/v) 
TEMED 9 µl 0.1% (w/v) 
H2O 4.2 ml  
                
                 Table 14. Stacking gel (6%) components 
Stacking gel (6%) component Volume Final concentration 
Tris-Cl (0.5 M, pH 6.8) 0.625 ml 375 mM 
Acrylamid 30% (w/v) 0.5 ml 10% (w/v) 
SDS 10% (w/v) 25 µl 0.1% (w/v) 
APS 10% (w/v) 12.5 µl 0.05% (w/v) 
TEMED 2.5 µl 0.1% 
H2O 1.34 ml  
 
3.2.15. Immunoblotting 
The proteins separated on the SDS-PAGE were transferred to nitrocellulose membrane 
and at 100V for 1 hour using a blotting apparatus. The membranes were blocked with 
5% non-fat milk for 1h at RT and probed with primary antibodies (diluted in TBST with 
5% BSA) at 4°C overnight. After three times washes with TBS containing 0.1% Tween-
20, horse radish peroxidase (HRP)-conjugated secondary antibodies (diluted in TBST 
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with 5% BSA) were applied for 1 hour at RT. Following washing, the blots were 
developed using an enhanced chemiluminescence (ECL) kit. The blots were captured 
by X-ray films and the intensity of bands was quantified by densitometry. Antibodies 
were listed as follows: TGF-β receptor I (1:1000, Cell Signaling), TGF-β receptor II 
(1:1000, Cell Signaling), SMAD2 (1:1000, Cell Signaling), SMAD3 (1:1000, Cell 
Signaling), fibronectin (1:1000, Sigma-Aldrich), collagen type I (1:1000, Meridian), β-
actin (1:4000, Abcam), α-SMA (1:1000, Abcam), SMAD2 (pSer465/467) (1:1000, 
Novus), SMAD3 (pSer423/425) (1:1000, Calbiochem), E-cadherin (1:1000, Millipore), 
HSP90α and HSP90β (1:1000, Enzo).  
 
                                  Table 15. Blotting buffer  recipe 
Blotting buffer Final concentration 
Tris-HCl 50 mM 
Glycine 40 mM 
Methanol 20% (v/v) 
 
                      Table 16. TBST buffer (pH 7.6) recipe 
TBST buffer ( pH 7.6) component Final concentration 
Tris-HCl 20 mM 
NaCl 150 mM 
Tween 0.1% (v/v) 
 
3.2.16. HSP90 inhibitors 
17-AAG and 17-DMAG are selective inhibitors for HSP90. In vitro experiments were 
carried out using 17-Allylamino-17-demethoxygeldanamycin (17-AAG) inhibitor. 17-
(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG) is a water- 
soluble derivative of geldanamycin which has excellent bioavailability and tissue 
distribution in animals and was applied in in vivo experiments.  
 
3.2.17. Immunohistochemistry 
Formalin-fixed, paraffin-embedded lung tissues were cut into sections with the 
thickness of 3 µm. After deparaffinization in xylene and rehydration in a series of 
grade-decreasing ethanol solutions, the sections were washed in distilled water. The 
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antigen retrieval was carried out by boiling the slides in citrate buffer (0.1 M citric acid 
monohydrate + 0.1 M Sodium citrate tribasic dihydrate). Next, the streptavidin-biotin-
alkaline phosphatase (AP) method with use of the ZytoChem-Plus AP Kit (Fast Red, 
red dye) or the streptavidin-biotin-HRP-method by using the ZytoChem-Plus HRP-DAB 
Kit (brown dye, both kits from Zytomed Systems, Berlin, Germany), according to a 
previously published protocol (Korfei et al., 2013). As control experiments, sections 
were treated with isotype IgG control (1:75, Acris Antibodies) to determine the 
specificity of the staining. To block the endogenous peroxidases, cells were treated 
with 3% hydrogen peroxide in methanol solution for 20 minutes. Further, slides were 
blocked with blocking solution (provided by the kit) for 5 minutes. Primary antibodies 
(diluted in PBS containing 2% BSA) such as: Hsp90α, Hsp90β and αSMA rabbit were 
applied for 3 hours.  
For staining of human lung tissue sections, the concentrations of primary antibodies 
were: α-SMA (1:150, Abcam), HSP90α (1:75, Enzo Life Sciences), and HSP90β 
(1:100, Abcam). For staining of murine lung tissue sections, the concentrations of 
primary antibodies were: α-SMA (1:100, Abcam), TTF1 (1:100, Abcam), HSP90α (1:70, 
Enzo Life Sciences), and HSP90β (1:100, Abcam). Double-IHC-stainings were 
performed on mice lung tissue sections for alpha-SMA (red dye, cytoplasmic staining of 
smooth muscle cells and myofibroblasts) and TTF1 (brown dye, nuclear staining of 
alveolar epithelial type-II cells (AECII)). 
After washing, the slides were treated with the corresponding biotinylated (polyvalent) 
antibody (diluted in solution provided by the kit) for 20 minutes and then with 
streptavidin-AP-conjugate for next 20 minutes. After washing, color development was 
carried out with Fast Red in Naphthlon solution, followed by counterstaining with 
hematoxylin. The sections were examined under a Leica DM 6000 B using Leica QWin 
imaging software. Sections from three mice and three donor/ IPF patients were stained 
with the representative staining shown. 1 x PBS (pH 7.4) was prepared for washes; 1 x 
PBS composition: 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4.                               
 
3.2.18. Immunocytochemistry 
1.5 x 104 human ILFBs were seeded in 8-well chamber slides. After serum-starvation 
for 24 hours, cells were stimulated with 10 ng/ml of human recombinant TGF-β 1 in the 
presence or absence of 50 nM 17-AAG for 72h. Further, cells were fixed with 4% 
paraformaldehyde (PFA) for 20 min at RT and permeabilized with 0.3% Triton-X100 in 
PBS containing 1% glycine at RT for 15 min. After three times washing steps cells were 
  
MATERIALS AND METHODS 
58 
 
blocked in blocking buffer (PBS containing 3% BSA and 0.05% Tween) for 1hr at RT. 
Cells were then incubated overnight at 4°C with primary antibodies: E-cadherin (1:100, 
BD Biosciences) and fibronectin (1:200, Sigma-Aldrich). Primary antibodies were 
diluted in blocking buffer. Next, cells were washed three times and DyLight 549-
conjugated secondary antibodies (1:5000, Zytomed, diluted in Fluorescence Antibody 
Diluent from the kit) were applied for 1 hour at RT followed by DAPI nuclear staining. 
For each antibody, the images were captured under the same exposure time and 
conditions by the Leica fluorescence microscope.  
  
3.2.19. Collagen assay 
Human ILFBs were plated in 6 cm dish. After serum-starvation for 24h, the cells were 
stimulated with 10 ng/ml of human recombinant TGF-β 1 in the presence or absence of 
50nM 17-AAG for 72h. Soluble collagen content in cells was assessed by Sircol 
collagen assay (Biocolor) according to manufacturer’s instructions. Briefly, cells were 
incubated with 0.5 M acetic acid and soluble collagen collected from the cells was 
stained with Sirius red dye.  The extracts were centrifuged at 12000 rpm for 10 min to 
precipitate collagen-Sirus red complexes. Next, pellet was washed with ice-cold acid-
salt wash reagent. The absorbance was measured at 555nm with the 
spectrophotometer. Amount of collagen was presented as µg, using a standard curve 
prepared from the kit at the same time.  
 
3.2.20. In vitro scratch assay 
Human ILFBs were seeded on 24-well plates. After serum-starvation for 24 hours, 
scratches were created using a p10 pipette tips. Next, cells were washed twice with 
PBS and cultured in medium containing 5% FCS in the presence or absence of 50 nM 
17-AAG. The images were captured by Leica realtime microscope system at the start 
of the experiment and every one hour until 24 hours later. Cell migration 
distance between the scratched line and the growing edge of the cells 
was measured at five points by Leica Application Suite Advanced Fluorescence (LAS 
AF) Microscope software. The migration rate was expressed in %. 
 
3.2.21. Transwell assay 
After serum-starvation for 24 hours, human ILFBs from donor and IPF patients were 
trypsinized and 1.2 × 104 cells were plated in 100 µl of MCDB-131, in the 6.5-mm 
transwell inserts with 8.0-µm pore size polycarbonate membrane. The lower chambers 
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were filled with 600 µl of serum-free medium alone or serum-free medium containing 
5% FCS or 5% FCS with 50nM 17-AAG inhibitor. All conditions were supplemented 
with 0.1% BSA. Further, fibroblasts were incubated at 37°C for 16 hours to allow cells 
to migrate through the membrane. Cells on the upper side of the inserts were removed 
with a cotton swab, whereas cells on the lower side of the inserts were fixed in 
3.7% PFA for 10 minutes followed by merging the insert in water. The migrated cells 
were then stained with 0.1% crystal violet in 20% methanol and were counted from 
nine randomly taken fields per membrane with the 20-fold magnification using Leica 
DM6000 B microscope. The migration rate was expressed in %. 
 
3.2.22. Co- immunoprecipitation 
ILFBs from patients with IPF were cultured in 10 cm dish. After serum-starvation for 24 
hours, cells were stimulated with 10 ng/ml of human recombinant TGF-β 1 in the 
absence or presence of 50 nM 17-AAG for 24 hours. Total proteins of donor ILFBs 
were isolated using cell lysis buffer (components are described in the table below). 
Dynabeads Protein G (Life Technologies) was incubated with TGF-β receptor II 
antibody (2 µg/ 0.75 mg of total proteins, Santa Cruz) or with IgG control antibody (2 
µg/ 0.75 mg of total proteins, Santa Cruz) for 1 hour at RT. The antibodies were diluted 
in PBST (PBS + 0.02% Tween 20).  
 
                           Table 17. Cell lysis buffer recipe 
Components of cell lysis buffer Final concentration 
Tris-HCl 50nM 
EDTA, pH 8 15mM 
NaCl 170nM 
Triton x100 0.1% 
Glycerol 20% 
 
Further, 0.75 mg of total proteins was applied and incubated with Dynabeads-TGF-β 
RII complexes overnight at 4°C. The precipitated complexes were washed three times 
using PBST (PBS containing 0.02% Tween 20) for each step and eluted by adding 50 
mM glycine, pH 2.8. Next, the complexes were  mixed  with  5 × SDS  gel  loading  
buffer at  a ratio  of 4:1 (v/v)  and denatured  at 100°C for 5 minutes. The experimental 
samples were separated by 8% SDS-PAGE and transferred to nitrocellulose 
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membranes. The membranes were blocked using 5% non-fat milk for 1 hour at RT and 
probed with TGF-β RII (1:1000, Santa Cruz) and HSP90β (1:1000, Enzo) antibody 
(diluted in TBST containing 5% BSA). Horse radish peroxidase (HRP)-conjugated 
secondary antibodies (diluted in TBST containing 5% BSA) were applied for 1 hour at 
RT. After three times washing, the blots were developed using an enhanced 
chemiluminescence (ECL) kit and were captured by films. The input lane represents 
5% of the protein used in co-immunoprecipitation.  
 
3.2.23. Statistics 
GraphPad Prism® v6.05 was used for all statistical analysis. Data are expressed, when 
appropriate, as mean ± SEM. Significance was assessed using unpaired t test (when 
two groups analyzed) or one-way ANOVA- Newman-Keuls test (for more than two 
groups). P < 0.05 was considered significant. 
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4. RESULTS 
4.1. Heat shock protein 90 (HSP90) expression at RNA level is not changed in 
human interstitial lung fibroblasts (hILFBs) and lungs derived from patients with 
interstitial lung fibrosis (IPF). 
To check the expression of HSP90 at RNA level in human, the real-time PCR was 
performed. Human interstitial lung fibroblasts (hILFBs) express similar level of 
HSP90AA1 and HSP90AB1 isoforms, except for HSP90B1 which is significantly up-
regulated in patients with IPF when compared with donors (Figure 12A). Similarly, 
relative mRNA level of all HSP90 isoforms in human lung homogenates is not altered 
(Figure 12B). There is no significant changes at transcriptional level in both human 
interstitial fibroblast (IFBs) and lung homogenates from donor and patients with IPF. 
                              
      A)                                                            B)  
                
 
 
 
Figure 12. HSP90 at RNA level is not changed in hILFBs and lungs from IPF patients. Relative 
mRNA levels of HSP90AA1, HSP90AB1 and HSP90B1 isoforms in (A) human interstitial lung fibroblast 
(ILFBs) and (B) human lungs from donor and patients with IPF were shown as delta Ct value after 
normalization to HPRT.  All values are expressed as mean ± SEM of n = 3 or n = 5 per group. ***P < 0.001 
versus Donor. 
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4.2. HSP90 at protein level is increased in ILFBs and lung homogenates from 
patients with IPF. 
Next the expression of HSP90 was examined at protein level in human ILFBs and 
lungs from donors and patients with IPF. In the initial protein expression profiling there 
was a significant up-regulation of the HSP90 isoforms (HSP90α and HSP90β) in both 
ILFBs (Figure 13A-13C) and lung homogenate from patients with IPF (Figure 13D-13F) 
compared with donors. 
        
                          A) 
 
 
 
 
 
       
 
                B)                                                       C) 
    
 
 
                             D)  
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                E)                                                           F) 
                           
 
Figure 13. HSP90 is increased in hILFBs and lungs from patients with IPF. Representative western 
blots with densitometry quantification of HSP90α and HSP90β in (A-C) human interstitial lung fibroblast 
(ILFBs) and (D-F) human lungs from donor and patients with IPF. β-actin serves as the loading control.  All 
values are expressed as mean ± SEM of n = 3 or n = 5 per group. *P < 0.05, **P < 0.01, ***P < 0.001 
versus Donor. 
 
4.3. HSP90 is up-regulated in myofibroblasts from lung of IPF patients. 
The up-regulated HSP90 expression at protein level was confirmed by 
immunochemistry. The staining revealed the presence of HSP90α and HSP90β in the 
pulmonary interstitium of donor and IPF lungs, but with an increased signal in 
myofibroblasts and fibroblast foci in the IPF lungs (indicated by asterisks and α-SMA 
positive staining of a serial sections; Figure 14). 
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Figure 14. HSP90 is up-regulated in human lung tissue sections from IF patients. Representative 
immunohistochemical staining of heat shock protein (HSP) 90α, HSP90β and α-smooth muscle actin (α-
SMA) in serial lung sections obtained from five organ donors and five patients with IPF. Myofibroblasts are 
shown by α-SMA (asterisks) staining. Red coloring indicates positive staining. Scale bar = 100 µm. 
 
4.4. 17-AAG reduces ILFBs transdifferentiation and collagen production. 
Having observed the upregulation of HSP90 in hILFBs from IPF patients, 17-AAG (a 
highly selective HSP90 inhibitor) was employed in vitro, to investigate the function of 
HSP90 on TGF-β1-induced fibrotic response in ILFBs, considering a central role of 
TGF-β1 in IPF. Western blots revealed that collagen I, fibronectin and α-SMA were all 
increased in hILFBs by the stimulation of TGF-β1, indicating fibroblast 
transdifferentiation and excessive extracellular matrix (ECM) production. This response 
was stronger in IPF ILFBs than in donor ILFBs (Figure 15A-15F). The effects of TGF-
β1 were blocked by co-administration of 17-AAG. Moreover, extracellular collagen 
deposition examined by Sircol collagen assay was 2-fold or 4-fold increased by TGF-β1 
in donor ILFBs or IPF ILFBs, respectively, and this increase was prevented by 17-AAG 
(Figure 15.G). Taken together, these results suggest that 17-AAG might suppress 
fibroblast transdifferentiation and collagen production.  
Additionally, HSP90 expression in hILFBs was not changed after in vitro treatment with 
17-AAG, which is consistent with the fact that HSP90 inhibitors only block the 
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chaperone ability of HSP90 rather than inhibit the expression (Figure 15A, 15F, 15G). 
Furthermore, proteomic analysis in previous studies showed induction of the HSP70 
family members after Hsp90 inhibition (Mayor-López et al., 2014), (Munje et al., 2014), 
therefore the level of HSP70 in in vitro experiment was investigated. The donor and IPF 
hILFBs treated with 17-AAG expressed higher level of HSP70 in comparison to 
untreated or TGF-β1-stimulated fibroblasts (Figure 15A, 15E). 
 
                       A) 
 
       
 
      B)                                                        C) 
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         D)                                                        E)  
 
 
 
          F)                                                       G)  
 
     
         
 
 
                         
                                   H) 
 
 
 
 
Figure 15. 17-AAG inhibits hILFBs transdifferentitation and collagen production induced by TGF-
β1. Expression of collagen I, fibronectin, α-SMA, HSP70, HSP90α and HSP90β expression detected by 
western blot (A) and quantified by densitometry using β-actin as the loading control (B-G). The level of 
protein expression is presented as the fold change from the level in the unstimulated cells which is 
presented as control. *P < 0.05, **P < 0.01 versus NTC; #P < 0.05, ##P < 0.01 versus TGF-β1. (H) 
Extracellular collagen production measured by Sircol soluble collagen assay. Collagen content is 
expressed as a percentage of collagen content in control group. ***P < 0.001 versus NTC, ###P < 0.001 
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versus TGF-β1. ILFBs were stimulated with recombinant TGF-β1 (10 ng/ml) for 24 hours (western blot) 
and 72 hours (Sircol collagen assay) in the absence or presence of 17-AAG (50 nM), following 24 hours of 
serum-starvation. Panels represent results from cells of three different donors and three different patients 
with IPF, and all values are given as the mean ± SEM of n = 3 per group. 
 
4.5. 17-AAG inhibits ILFBs migration induces by FCS. 
Uncontrolled fibroblast migration is a pathological feature during the progressive 
pulmonary fibrosis, so the effect of 17-AAG on ILFBs migration by transwell assay was 
determined. The migration was increased after FCS stimulation in both donor and IPF 
ILFBs, while the treatment with 17-AAG inhibits significantly the migration by 
approximately 70% in both donor and IPF ILFBs (Figure 16A-16B). 
Additionally, cell migration monitored by real-time microscope in the scratch assay 
demonstrated a 60% and 70% decrease of FCS-induced gap closure after 17-AAG 
treatment in donor and IPF ILFBs, respectively (Figure 16C, 16D), which was 
consistent with the transwell results. These data strongly suggests that 17-AAG 
suppresses FCS-induced migration of ILFBs. 
 
                    A) 
   
               
                               B) 
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C) 
 
 
                                          D) 
 
 
 
Figure 16. 17-AAG inhibits hILFBs migration induced by FCS. (A-B) ILFB transwell migration induced 
by fetal calf serum (FCS). The migration rate is expressed as a percentage of the migration rate in FCS-
stimulated cells. Representative images of cells on transwell membranes were taken using light 
microscopy. Scale bar = 100 µm. (C-D) Images of the scratch at the same position were captures every 
hour and the degree of gap closure of both donor and patients with IPF. The migration rate is expressed 
as a percentage of the migration rate in FCS-stimulated cells. Representative images at the time of scratch 
0 hours and 8 hours were shown. ILFBs were stimulated with FCS for 8 hours (scratch assay) or 16 hours 
(transwell assay) in the absence or presence of 17-AAG (50 nM) following 24 hours of serum-starvation. 
All panels represent results from cells of three different donors and three different patients with idiopathic 
pulmonary fibrosis (IPF), and all values are given as the mean ± SEM of n= 3 per group. ***P < 0.001 
versus Control; ###P < 0.001 versus FCS. 
 
4.6. 17- AAG blocks TGFβ/Smad signaling in IFBs by diminishing TGF-βRs levels 
by proteasome degradation.  
TGF-β receptor I and/or TGF-β receptor II were suggested to be potential target 
proteins chaperoned by HSP90 in cancer cell studies (Zhang et al., 2012; Tomcik et al., 
2014), therefore the next question was asked if the same regulation applies to IFBs. 
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Stimulation of IPF ILFBs with TGF-β1 led to increased levels of TGF-βRI and TGF-
βRII, both of which were reduced to control levels by co-administration of 17-AAG 
along with Smad2/3 activation indicated by Smad2 phosphorylation (Figure 17A-17D). 
However, donor ILFBs showed only mild decrease of TGF-βRI when treated with 17-
AAG. Nevertheless, TGF-β1-induced Smad2/3 activation indicated by Smad2 
phosphorylation was blocked by 17-AAG in both donor and IPF ILFBs (Figure 17A-
17D). More interestingly, 17-AAG-induced loss of TGF-βRs and Smad3 
phosphorylation were restored by MG-132, a proteasome inhibitor (Figure 17E). These 
data suggest that 17-AAG blocks the TGF-β/Smad signaling by disrupting the stability 
of TGF-βRs and promoting proteasome degradation.  
 
                  A) 
 
 
 
         B)                                                      C) 
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                                 D) 
 
 
 
 
                            
                     E)  
 
 
Figure 17. 17-AAG blocks TGFβ/Smad signaling in hILFBs by diminishing TGF-βRs levels by 
proteasome degradation. (A-D) Western blot analysis of TGF-β receptor I (TGF-βRI), TGF-β receptor II 
(TGF-βRII), phospho-Smad2 (phospho-Ser465, phospho-Ser467) and Smad2. β-actin serves as the 
loading control. The level of protein expression is shown as the fold change from the level in the control 
group. All panels represent results from cells of three different donors and three different patients with 
idiopathic pulmonary fibrosis (IPF), and all values are given as the mean ± SEM of n = 3 per group. *P < 
0.05, **P < 0.01, ***P < 0.001 versus Control; #P < 0.05, ##P < 0.01, ###P < 0.001 versus TGF-β1.  (E) 
Representative WB analysis of TGF-β receptor I (TGF-βRI), TGF-β receptor II (TGF-βRII), phospho-
Smad3 (phospho-Ser423, phospho-Ser425) and Smad3. β-actin serves as the loading control. The 
experiment was repeated independently three times in one donor and one patient with IPF.  After 24 hours 
of serum-starvation, ILFBs were stimulated with recombinant TGF-β1 (10 ng/ml) for 24 hours (western 
blots), in the absence or presence of 17-AAG. For MG-132 experiment, ILFBs were treated with 17-AAG 
(50 nM) in the absence or presence of MG-132 (30 µM) for 5 hours, followed by 1 hour stimulation with 
TGF-β1.              
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4.7. HSP90β interacts with TGF-βRII in hILFBs.     
To further delineate whether HSP90 directly interacts with TGF-βRs and acts as a 
molecular chaperone, endogenous co-immunoprecipitation was performed in donor 
and IPF ILFBs followed by western blotting, which revealed that HSP90β was 
specifically co-immunoprecipitated by TGF-βRII in both cells (Figure 18A). More 
importantly, the binding TGF-βRII and HSP90β was profoundly disrupted by 17-AAG. 
Taken together, the results suggest that HSP90 regulates TGF-β/Smad signaling by 
stabilizing TGF-βRs via direct interaction with TGF-βRII. 
                            
                                   A)                             
              
         
                                            
 
Figure 18. HSP90β interacts with TGF-βRII in hILFBs. (A) Western blots of heat shock protein 
HSP90β and TGF-βRII after protein lysate from donor and IPF ILFBs was immunoprecipitated with anti-
TGF-βRII antibody or IgG antibody. After 24 hours of serum-starvation, ILFBs were stimulated with 
recombinant TGF-β1 (10 ng/ml) for 24 hours in the absence or presence of 17-AAG.  
 
4.8. 17-AAG prevents epithelial-mesenchymal transition (EMT) of A549 cells. 
Except for the residential interstitial fibroblasts in the lung, epithelial-mesenchymal 
transition (EMT) has been implied as a source of myofibroblasts (Fernandez and 
Eickelberg, 2012b). The study was also directed toward the effect of 17-AAG on TGF-
β1-induced EMT of A549 cells, which is a model of human alveolar type-II epithelial 
  
RESULTS 
72 
 
cells. A549 cells without exposure to TGF-β1 exhibited a cubic cell shape in cluster 
formation (epithelial phenotype); administration of TGF-β1 caused the cells to develop 
an individualized, elongated spindle-shape, whereas cells exposed to TGF-β1 and 
concomitant 17-AAG retained the epithelial phenotype (Figure 19A). Additionally, 
immunofluorescence staining (Figure 19A) and western blotting (Figure 19B-19F) 
demonstrated that TGF-β1 exposure led to elevation of the mesenchymal marker- 
fibronectin (Figure 19C) and reduction of the epithelial marker- E-cadherin (Figure 19D)  
in A549 cells, indicating an on-going EMT event. The shift of markers induced by TGF-
β1 was prevented by co-administration of 17-AAG, concomitant with decreased TGF-
βRII expression and Smad2 phosphorylation (Figure 19E-19F).               
   
              A) 
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                    B) 
 
 
 
                 C)                                                 D) 
         
                                 
 
                   E)                                                F) 
            
 
Figure 19. 17-AAG prevents TGF-β1-induced EMT of A549 cells. (A) Representative images of A549 
cell morphology examined by phase contrast microscopy under 20 x magnification (upper panel) and 
representative immunofluorescence staining of E-cadherin (red) and fibronectin (red) with DAPI (blue) 
counter-staining for nuclei (lower 2 panels). Scale bar = 20 µm. (B-F) Representative western blots of E-
cadherin, fibronectin, TGF-β receptor II (TGF-βRII), phospho-Smad2 (phospho-Ser465, phospho-Ser467), 
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and Smad2, with β-actin as the loading control. A549 cells were stimulated with TGF-β1 (5 ng/ml) for 72 
hours in the absence or presence of 17-AAG (50 nM) after 24 hours of serum-starvation. All values are 
given as the mean ± SEM of n = 3 per group. The experiment was repeated independently three times. *P 
< 0.05, **P < 0.01, ***P < 0.001 versus Control; ###P < 0.001 versus TGF-β1. 
 
4.9. Administration schedule using 17-DMAG on the bleomycin-induced 
pulmonary fibrosis model. 
Based on the fact that HSP90 plays an important role in ILFB transdifferentiation and 
EMT by manipulating the TGF-β pathway, and HSP90 inhibition with 17-AAG blocks 
the fibrotic response to TGF-β in vitro, the in vivo studies with 17-DMAG were carried 
out, a water-soluble HSP90 inhibitor, in mice with bleomycin-induced pulmonary 
fibrosis. Animals were divided in the following four groups: 
I. Control mice- received instillation of sterile saline at day 0 and was given 
vehicle alone (saline);  
II. Bleomycin-administrated mice- received bleomycin at day 0 and were given 
vehicle;  
III. Mice treated with 10 mg/kg 17-DMAG- received bleomycin at day 0 and were 
treated every second day from day 8 for 2 weeks with 10 mg/kg.  
IV. Mice treated with 25 mg/kg 17-DMAG- received bleomycin at day 0 and were 
treated every second day from day 8 for 2 weeks with 25 mg/kg.  
17-DMAG was prepared freshly in saline at 2 or 5 mg/ml and administrated per os via 
gavage needle, all in the same manner. 
 
 
 
 
Figure 20. Schedule using 17-DMAG in the bleomycin-induced pulmonary fibrosis model. 
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4.10. HSP90 at RNA level is not up-regulated in ILFBs and lungs from bleomycin- 
challenged mice. 
To investigate the transcriptional level of HSP90 in mouse, the real-time PCR was 
carried out. There was no differences in the expression of HSP90AA1, HSP90AB1 and 
HSP90B1 isoforms between sham control and bleomycin-challenged mice, in both 
mouse interstitial fibroblasts (Figure 21A) and lung homogenate (Figure 21B). 
                                                   
       A)                                                              B) 
              
 
 
 
Figure 21. HSP90 at RNA level is not up-regulated in mILFBs and lung homogenates from 
bleomycin-challenged mice. (A) Relative mRNA levels of HSP90AA1, HSP90AB1 and HSP90B1 in 
mouse ILFBs and (B) mouse lungs from sham control and bleomycin-challenged mice (Bleo) presented as 
delta Ct value after normalization to HPRT. All values are expressed as mean ± SEM of n= 3 per group. 
 
4.11. HSP90 is increased at protein level in ILFBs and lung homogenates from 
bleomycin- challenged mice. 
Next, the expression of HSP90 in the 21-day bleomycin-challenged mice was 
examined. Western blots demonstrated a 2-fold increase of HSP90α and HSP90β in 
ILFBs from bleomycin-challenged mice (Figure 22A-22C) and no significant differences 
in the expression of HSP90 in lung homogenates from bleomycin-challenged mice 
(Figure 22D-22F) when compared with sham control. 
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                            A)
 
 
         
 
 
 
 
       B)                                                            C) 
           
 
 
                             D) 
 
 
 
 
 
 
 
         E)                                                           F)                 
                
 
Figure 22. HSP90 is increased in mILFBs and lung homogenates from bleomycin- challenged mice. 
Representative western blots of HSP90α and HSP90β in (A-C) mouse ILFBs and (D-F) mouse lungs from 
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sham and bleomycin-challenged mice (Bleo), with densitometry quantification. β-actin serves as the 
loading control. All values are expressed as mean ± SEM of n= 3 in the group. *P < 0.05 vs Sham. 
 
4.12. HSP90 is up-regulated in myofibroblasts from lung of bleomycin-challenged 
mice. 
The expression of HSP90 in the lungs of bleomycin-challenged mice and sham 
controls was examined. Immunohistochemistry exhibited increased interstitial 
immunoreactivity of HSP90α and HSP90β in myofibroblasts (indicated by asterisks and 
α-SMA staining of a serial section) in the lungs of bleomycin-challenged mice 
compared with sham controls (Figure 23). In addition, a pronounced overexpression of 
HSP90β (but not HSP90α) was observed in AECII in bleomycin-challenged lungs 
(indicated by arrows and TTF1 staining) compared with sham controls (Figure 23). 
 
 
 
 
Figure 23. HSP90 is up-regulated in lung tissue sections from bleomycin-challenged mice. 
Representative immunohistochemical staining of HSP90α, HSP90β, TTF1 and α-SMA in serial lung 
sections obtained from three sham controls and three bleomycin-challenged mice (Bleo). Myofibroblasts 
and AECII are shown by α-SMA (asterisks) and TTF1 (arrows) staining, respectively. Red coloring 
indicates positive staining for Hsp90α, Hsp90β and α-SMA; brown coloring for TTF1. Scale bar = 50 µm. 
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4.13. TGF-β RI, TGF-β RII and TGF-β1 at RNA level is not changed in mouse 
homogenate after treatment with 17-DMAG. 
It was shown in this study that the antifibrotic effects of HSP90 inhibitor were a 
consequence of significant depletion of TGF-β receptors on the post-translational level. 
To prove that there are not changes on the transcriptional level, RT-PCR was 
performed. The results indicated that there was no differences in expression of TGF-
β1, TGF-β receptor I and receptor II at RNA level between sham control, bleomycin-
challenged mice and mice treated with both doses of 17-AAG (10 mg/kg and 25 mg/kg; 
Figure 24A-24C). 
 
   A)                                                              B) 
               
                                 C) 
                                    
Figure 24. TGF-β RI, TGF-β RII and TGF-β1 at RNA level is not changed in mouse lung homogenate 
after the 17-DMAG treatment. (A-C) Relative mRNA levels of TGF-β RI, TGF-β RII and TGF-β1 in mouse 
lung homogenates from sham control, bleomycin-challenged mice (Bleo) and mice treated with 17-DMAG 
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(10 mg/kg and 25 mg/kg) presented as delta Ct value after normalization to HPRT. All values are 
expressed as mean ± SEM of Sham= 6, Bleo= 9, 10 mg/kg= 9, 25 mg/kg= 8.  
 
4.14. HSP90 expression at the protein level is not changed in the mouse 
homogenate after treatment with 17-DMAG. 
WB was performed to check if the protein level of HSP90 was unaltered after the in 
vivo treatment with 17-DMAG. The expression supposes to be equal because the 
Hsp90 inhibitor only disrupts protein interactions between HSP90 and its clients, it does 
not affect protein level of Hsp90 itself. Indeed, these data indicated that the HSP90 
level is unaltered in bleomycin-challenged mice treated with the both doses of 17-
DMAG (10 mg/kg and 25 mg/kg) when compared with sham controls or bleomycin-
challenged mice (Figure 25A-25C).  
 
                 A) 
 
                                      
            B)                                                       C) 
           
 
Figure 25. HSP90 expression at the protein level is not changed in the mouse lung homogenate 
after treatment with 17-DMAG. (A) Representative western blots of HSP90α and HSP90β with 
densitometry quantification (B-C)) in mouse lung homogenates from sham control, bleomycin-challenged 
mice (Bleo) and mice treated with 17-DMAG (10 mg/kg and 25 mg/kg) with densitometry quantification. β-
actin serves as the loading control.  All values are expressed as mean ± SEM of n= 3 or n= 4 per group.  
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4.15. HSP70 protein expression is up-regulated in the homogenate from 
bleomycin-administrated mice after treatment with 17-DMAG. 
Proteomic analysis in previous studies showed induction of the HSP70 family members 
after Hsp90 inhibition (Mayor-López et al., 2014); (Munje et al., 2014). The level of 
HSP70 was investigated in this study. The bleomycin-challenged mice treated with 
both doses of 17-DMAG (10 mg/kg and 25 mg/kg) expressed higher level of HSP70 
when compared with sham or bleomycin-administrated mice (Figure 26A and 26B). 
 
                      A) 
 
                                        
                        B)                                                           
 
 
Figure 26. HSP70 protein expression is upregulated in the homogenate from bleomycin-
administrated mice after treatment with 17-DMAG. (A-B) Representative western blots of HSP70 with 
densitometry quantification in mouse lung homogenates from sham control, bleomycin-challenged mice 
(Bleo) and mice treated with 17-DMAG (10 mg/kg and 25 mg/kg) with densitometry quantification. β-actin 
serves as the loading control.  All values are expressed as the mean ± SEM of n= 3 or n= 4 mice per 
group.  ***P < 0.001 versus Sham; ###P < 0.001 versus Bleo.  
 
4.16. 17-DMAG suppresses inflammation in bleomycin-challenged mice. 
Bleomycin-induced pulmonary fibrosis model is initiated by a severe acute injury and 
inflammatory response, followed by chronic inflammation and fibrosis (Scotton and 
Chambers, 2010), therefore the inflammatory cell composition of BALF collected on 
day 21 was analyzed. The cell counting revealed increased proportions of lymphocytes 
and neutrophils, at the expense of the proportion of macrophages, in bleomycin-
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challenged mice compared with sham controls. 17-DMAG partially restored the 
inflammatory cell composition in BALF (Figure 27A-27C), suggesting a favorable effect 
of HSP90 inhibition on sustained pulmonary inflammation  in  bleomycin-challenged 
mice. 
 
 
  A)                                                                   B) 
              
   
                                        C)                         
 
                                  
Figure 27. 17-DMAG suppresses inflammation in bleomycin-challenged mice. (A-C) Infiltrated 
inflammatory cells in bronchoalveolar lavage fluid (BALF) were counted. At day 21 after instillation of 
bleomycin (Bleo) or saline (Sham), in the absence or presence of 17-DMAG treatment (10 mg/kg or 25 
mg/kg every 2 days from day 8 to day 21). All values are given as the mean ± SEM of n= 10 mice in each 
group. *P < 0.05, ***P < 0.001 versus Sham; #P < 0.05, ##P < 0.01, ###P < 0.001 versus Bleo. 
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4.17. 17-DMAG improves physiological parameters in mice with bleomycin-
induced pulmonary fibrosis. 
Bleomycin causes significant loss of body weight (up to 20%) one week after 
instillation. The body weight gain of 17-DMAG-treated mice was effectively improved 
compared with bleomycin-challenged mice (Figure 28A). Moreover, lung function 
monitored by FlexiVent exhibited a significant decrease of lung compliance in 
bleomycin-chalenged mice compared to sham (0.025 mL/cmH2O ± 0.006 vs 0.035 
mL/cmH2O ± 0.005), and 17-DMAG dose-dependently ameliorated lung compliance 
(0.0283 mL/cmH2O ± 0.0067 in 10 mg/kg group and 0.0325 mL/cmH2O ± 0.0046 in 25 
mg/kg group mice; Figure 28B). 
Further, tissue damping was elevated in bleomycin-treated mice in comparison to sham 
control (5.77 cmH2O/mL ± 0.43 vs 4.39 cmH2O/mL ± 0.2). The treatment with both 
doses of 17-DMAG improves the tissue damping (5.17 cmH2O/mL ± 0.18 in 10mg/kg 
group and 4.63 cmH2O/mL ± 0.19 in 25 mg/kg group; Figure 28C). These results 
showed that 17-DMAG restores the impaired lung function. 
 
 
                                A)  
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  B)                                                                C) 
            
       
Figure 28. 17-DMAG treatment improves lung function in bleomycin-challenged mice. (A) Body 
weight curve monitored throughout the whole experiment, (B) Lung compliance and (C) lung tissue 
damping, measured at day 21 after instillation of bleomycin (Bleo) or saline (Sham),  in the absence or 
presence of 17-DMAG treatment (10 mg/kg or 25 mg/kg every 2 days from day 8 to day 21). All values are 
given as the mean ± SEM of n= 10 mice in each group. **P < 0.01, ***P < 0.001 versus Sham; #P < 0.05, 
##P < 0.01 versus Bleo. 
 
4.18. 17-DMAG decreases fibrosis scores and collagen deposition in bleomycin-
challenged mice. 
To understand the role of HSP90 in lung parenchyma remodeling, a comprehensive 
histological evaluation was carried out. Hematoxylin and eosin (H&E) staining revealed 
a significant distortion of bleomycin-challenged lungs, while 17-DMAG partially restored 
the lung architecture (Figure 29A). The fibrosis score demonstrated a moderate degree 
of fibrosis in bleomycin-challenged mice compared with sham controls (3.83 ± 0.56 
versus 0.50 ± 0.14; Figures 29A and 29B). 17-DMAG dose-dependently decreased 
fibrosis scores (3.06 ± 0.38 in the 10 mg/kg group and 2.85± 0.25 in the 25 mg/kg 
group). Based on the pronounced effect of 17-AAG on collagen production in vitro, 
collagen deposition in vivo was further examined using sirius red staining. Bleomycin-
challenged mice exhibited excessive collagen deposition compared with sham controls 
(4.64% ± 0.56 versus 0.94% ± 0.19), whereas 17-DMAG treatment narrowed the 
collagen areas (2.33% ± 0.58 in the 10 mg/kg group and 2.19% ± 0.54 in the 25 mg/kg 
group; Figures 29A and 29C). 
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   A) 
 
 
B)                                                            C  
    
           
Figure 29. 17-DMAG treatment decreases fibrosis scores and collagen deposition in bleomycin-
challenged mice. (A) Histological images of lung paraffin sections with hematoxylin and eosin (H&E) 
staining for pulmonary fibrosis (upper 2 panels) and sirius red staining for collagen deposition (lower 
panel). Scale bar = 20 µm. (B) Fibrosis score (based on H&E staining) expressed on a numerical scale 
ranging from 0 (healthy) to 6. (C) Collagen content (based on sirius red staining) expressed as a 
percentage of the total area of lung section. All values are given as the mean ± SEM of n = 10 mice per 
group. **P < 0.01, ***P < 0.001 versus Sham; #P < 0.05, ##P < 0.01, ###P < 0.001 versus Bleo. 
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4.19. 17-DMAG suppresses metalloproteinase (MMP) activity in bleomycin-
challenged mice.  
MMP-associated proteinase activity is reported to reflect inflammation and IPF patients 
show elevated MMPs levels in BALF (Dancer et al., 2011), (McKeown et al., 2009). To 
monitor the MMP activity in vivo, a MMP-responsive probe, named MMP680Sense, 
was introduced into mice and measured the signal with FMT. MMP activity was 
increased in lungs from bleomycin-challenged mice compared with sham control (4.67 
pmol ± 1.22 vs 0.54 pmol ± 0.24). Mice treated with 17-DMAG after the bleomycin 
challenge showed lower MMP activity (2.11 pmol ± 1.44 in the 10 mg/kg group and 
0.99 pmol ± 0.66 in the 25 mg/kg group; Figure 28A-28C). 
                               
     A) 
 
        
       B)                                                              C) 
       
                                                                                     
 
Figure 30. 17-DMAG suppresses metalloproteinase (MMP) activity in bleomycin-challenged mice. 
(A) Representative images of MMP activity in mouse lungs. (B) Virtual 3D rendering of skeleton, lungs and 
MMP activity in bleomycin-challenged lung acquired by FMT in combination with microcomputed 
tomography (µCT). (C) Quantitative FMT measurement of MMP activity in mouse lungs. MMP activity in 
mouse lungs was measured in vivo by quantitative fluorescence molecular tomography (FMT) at day 21 
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after instillation of bleomycin (Bleo) or saline (Sham), in the absence or presence of 17-DMAG treatment 
(10 mg/kg or 25 mg/kg every 2 days from day 8 to day 21). MMP activatable fluorescent probe, 
MMPSense680, was injected via the tail vein 24 hours before the FMT measurement. All values are given 
as the mean ± SEM of n = 5 mice. ***P < 0.001 versus Sham; ###P < 0.001 versus Bleo
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5. DISCUSSION 
This study provides direct experimental proof that HSP90 plays a pathological role in 
pulmonary fibrosis. HSP90 inhibition presents antifibrotic effects in vitro by preventing 
the myofibroblasts transdifferentiation from both fibroblasts and alveolar epithelial cells. 
Furthermore, the treatment of bleomycin-induced pulmonary fibrosis mice with HSP90 
inhibitor shows significant antifibrotic effects in vivo.    
 
5.1. HSP90 expression 
HSP90 has a broad spectrum of pathophysiological functions depending on cell types 
and stresses. HSP90 has been intensively studied in tumors. Many tumor-promoting 
factors are HSP90-dependent and cancer cell proliferation relies on HSP90 function. 
Cancer cells proliferate faster and need rigorously HSP90 function, while healthy cells 
rely on HSP90 modestly. This phenomenon is termed ‘HSP90 addiction’. The role of 
HSP90 has been investigated in other diseases such as neurodegenerative and 
infectious diseases.  In neurodegenerative diseases, HSP90 stabilizes p53 and lead to 
abnormal tau phosphorylation and directly interacts with mutated form of tau protein. 
Thus it influences the accumulation of toxic tau aggregates in tauopathy like 
Alzheimer’s disease (AD) and frontotemporal dementia (FTD) (Dickey et al., 2007). In 
viral infections HSP90 plays a key role in folding of basic viral proteins (Geller et al., 
2007) and HSP90 inhibitors can block the replication of poliovirus  and paramyxovirus 
(Geller et al., 2013). However, little is known on the role of HSP90 in pulmonary 
fibrosis. 
 
To better understand the pathophysiology of IPF, many studies have tried to identify 
molecules by comparing the transcriptome or proteome of healthy lungs and lungs 
derived from IPF patients (Korfei et al., 2013). In the 2-D gel proteomic study, Korfei 
and colleagues have reported that HSP90 along with other stress-related proteins such 
as HSP27 was elevated in IPF lungs (Korfei et al., 2013); however the function of 
HSP90 in IPF has not been elucidated. In this study, theup-regulation of HSP90 was 
observed in IPF lungs, more interestingly up-regulated protein expression of both 
HSP90α and HSP90β was found in ILFBs from IPF patients as well as from human 
lung homogenate. Moreover, ILFBs derived from bleomycin-administrated mouse 
exhibit significantly increased level of both isoforms of HSP90.  
Additionally, in this study the protein level of HSP90 was not changed neither after in 
vitro treatment with 17-AAG in donor and IPF ILFBs nor after in vivo treatment of 
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bleomycin-administrated mice with 17-AAG. This situation takes places because the 
Hsp90 inhibitor only disrupts protein interactions between Hsp90 and its clients, it does 
not change the protein level of Hsp90 itself. Similarly, the increased expression of 
HSP90α and HSP90β was detected by immunochemistry in patients with systemic 
sclerosis (SSc) and in experimental fibrosis in a transforming growth factor β (TGF-β)-
dependent manner (Tomcik et al., 2014).  
 
5.2. TGFβ signaling in pulmonary fibrosis 
It is well known that TGF-β is actively involved in initiation and progression of 
pulmonary fibrosis (Fernandez and Eickelberg, 2012b), (Khalil et al., 1996), therefore 
inhibition of aberrant TGFβ signaling cascade has long been pursued as a potential 
strategy for the treatment of pulmonary fibrosis, among other fibrotic diseases. Despite 
of intensive in vivo investigations or even clinical trials, attempts to directly block TGF-β 
signaling by either TGF-β neutralizing antibodies (Khalil et al., 1996) or TGFβR kinase 
inhibitors  (Bonniaud et al., 2005) have thus far been ineffective or are still in the 
experimental stage. To overcome this challenge, it is of great interest to identify other 
mediators of TGF-β signaling which can be targeted pharmacologically. HSP90 was 
proposed as such a mediator and HSP90 inhibitor as a novel therapeutic approach for 
pulmonary fibrosis. 
 
5.3. 17-AAG reduces extracellular matrix (ECM) production 
During the progress of pulmonary fibrosis, a range of cellular abnormalities are present 
in the lung, one of which is myofibroblasts transdifferentiation. As the effector cells, 
myofibroblasts are mostly responsible for EMC production, remodelling and fibrotic foci 
formation (Fernandez and Eickelberg, 2012a). Having observed the upregulation of 
HSP90 in pulmonary fibrotic lungs or ILFBs, we employed 17-AAG, a highly selective 
HSP90 inhibitor, in vitro to investigate the function of HSP90 on TGF-β1-induced 
fibrotic response in hILFBs, considering TGF-β1 plays a central role in IPF. Western 
blots revealed that collagen I, fibronectin and α-SMA were all increased in hILFBs 
under the stimulation of TGF-β1 indicating fibroblast activation and excessive ECM 
production, with a higher level on IPF hIFBs compared to the donor cells. And the 
effects of  TGF-β1  were  sufficiently  blocked  by  17-AAG.  Moreover, extracellular 
collagen deposition examined by sircol red assay was increased by TGF-β1 in both 
donor hILFBs and IPF hILFBs and was reversed to the basal level by 17-AAG. 
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Similarly, in a study on systematic sclerosis, 17-DMAG was shown to block TGF-β1-
induced mRNA expression of collagen and fibronectin in skin fibroblasts (Tomcik et al., 
2014). Further, Noh and colleagues described in renal NRK49F fibroblasts increased 
level of TGFβ1-induced ECM production, while the treatment with 17-AAG inhibited  
the expression of collagen I, fibronectin and α-SMA (Noh et al., 2012). In hepatic 
fibrosis, Myung and colleagues showed that α-SMA protein expression was 
suppressed by the treatment with 17-AAG what indicated that the inhibitor prevented 
HSC (hepatic stellate cells) cell activation. Additionally, TGF-β1-induced collagen 
synthesis on RNA level was suppressed by 17-AAG in HSC cells which are main 
source of ECM proteins in hepatic fibrosis (Myung et al., 2009).  
 
5.4. 17-AAG inhibits fibroblast migration 
Besides myofibroblasts transdifferentiation and ECM production, one other pathological 
features of fibroblasts contributing to pulmonary fibrosis are uncontrolled migration 
which is also a feature of cancer cells (Vancheri et al., 2010; Vancheri, 2013).  HSP90 
inhibitor suppress tumor growth and metastasis via abrogating proliferation and mobility 
(Fortugno et al., 2003)(Annamalai et al., 2009). Annamalai and colleagues 
demonstrated that HSP90 may regulate the activity of EphA2 and presented the 
potential interaction between EphA2 receptor signaling and chaperone function. 
Geldanamycin reduced the migration of U251 (human malignant glioblastoma) cell line 
suggesting that EphA2 signaling plays a major role in HSP90-dependent cell migration 
(Annamalai et al., 2009). Nagaraju and colleagues investigated the role of HSP90 in 
colorectal cancer. The treatment with HSP90 inhibitor (ganetespib) inhibited migration 
in HCT-116 (human colon carcinoma) cell line. Moreover, the effect of ganetespib on 
cellular pathways involved in motility were evaluated. Phosphorylated S6K and FAK 
was down-regulated at both RNA and protein level (Nagaraju et al., 2014).  
 
5.5. 17-AAG reverses epithelial-mesenchymal transition (EMT) 
The origin of myofibroblasts remains unclear (Willis et al., 2005). There are three 
theories that seek to explain the origin of myofibroblasts:  activated resident lung 
fibroblasts, epithelial cells via the process of EMT and bone marrow–derived fibrocytes.   
Myofibroblasts have been long believed to arise through transdifferentiation of 
residential parenchymal fibroblasts, initiated by multiple growth factors or cytokines 
such as PDGF, FGF and TGF-β (Fernandez and Eickelberg, 2012a). Compelling 
evidence has also suggested that alveolar epithelial cells may transdifferentiate to 
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myofibroblasts by activation of TGF-β signaling (Willis et al., 2005)  or Wnt signaling 
(Königshoff et al., 2009), by process referred as EMT. However, the relative 
quantitative contribution of each cell types in the onset and progression of IPF is 
unknown. Reporter mice with marked cells of lung epithelial lineage with β-
galactosidase were created to study EMT, and bone marrow chimeras expressing 
green fluorescent protein under the control of the fibroblast-associated S100A4 
promoter were generated to examine bone marrow–derived fibroblasts. In bleomycin-
induced fibrosis in mice, EMT comprised about 33% of fibroblasts and bone-marrow 
progenitors (fibrocytes) accounted for 20% of fibroblasts. It can be speculated, that 
50% of fibroblasts originate from resident mesenchymal cells or other undisclosed 
source, at least in this model (Tanjore et al., 2009).  
 
The association of EMT with the cancer progression has been investigated in various 
types of cancer such as breast cancer, prostate cancer, pancreatic cancer and 
hepatoma (Lamouille et al., 2014). Several studies have also revealed the association 
between loss of E-cadherin expression and poor prognosis in lung cancer (Xiao and 
He, 2011).  Balanis and colleagues showed that the EMT is capable to increase the 
invasion and metastasis of breast cancer cells via activation of Stat3. Moreover, cancer 
cells undergo fibronectin production that supports Stat3 activation and metastatic 
outgrowth (Balanis et al., 2013). Further, Nagaraju and colleagues proved the inhibition 
of EMT in the animal model, in HCT-116 and HT-29 xenograft. Tumors resected from 
the gantespib-treated mice had significantly down-regulated expression of vimentin and 
increased E-cadherin when compared with untreated mice (Nagaraju et al., 2014).   
Based on the close association of HSP90 with the EMT in cancer metastasis, this study 
was directed toward the effect of 17-AAG on TGF-β1-induced EMT by applying A549 
cells (human pulmonary epithelial cells). And our results confirm this theory, showing 
that 17-AAG reversed the switch between the epithelial and mesenchymal markers 
induced by TGF-β1, at the expense of TGF-βR2 and Smad2 activation. A549 cells 
under untreated conditions present a cubic epithelial shape in cluster formation 
compared with an individualized, elongated and spindle shape after TGF-β1 
stimulation, whereas 17-AAG restored A549 cells to the epithelial phenotype. 
Additionally, TGF-β1 led to elevated mesenchymal marker (fibronectin) and diminished 
epithelial marker (E-cadherin) in A549 cells indicating an on-going EMT event, 
demonstrated by immunofluorescence staining and western blots. The shift of markers 
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induced TGF-β1 by was reversed by 17-AAG, accompanied by decreased TGF-β 
receptor II expression and SMAD2 phosphorylation. 
 
The role of HSP27, another family of HSP proteins, was also studied in fibrogenesis 
and EMT. HSP27 was reported to bind to and stabilize Snail and consequently 
contribute to EMT. HSP27 knockdown caused Snail proteosomal degradation, thus 
blocking TGF-β-induced EMT. Wettstein and colleagues also demonstrated that 
HSP27 is up-regulated in patients suffered from IPF and in different in vivo models. 
The inhibition of HSP27 with OGX-427 (in phase II clinical trials as anticancer 
compound)  efficiently inhibited EMT and fibrosis development (Wettstein et al., 2013).  
 
5.6. HSP70 expression 
Heat shock protein 70 (HSP70) is involved in the protection against various stressors 
and has anti-inflammatory activity. A wide variety of stresses, for example ischemia 
and inflammation, induce the up-regulation of HSPs including HSP70. HSP70 in 
particular has been showed to be involved not only in cytoprotective function via anti-
apoptosis processes against stress in vitro , but also influence strong cytoprotection in 
the stomach, heart and liver in vivo (Otaka et al., 2007; Suemasu et al., 2009). It has 
been investigated the protective role of HSP70. Tanaka and colleagues found that 
transgenic mouse overexpressing HSP70 exhibit the blockade of the bleomycin-
induced pulmonary inflammatory response and tissue damage. Moreover, HSP70 
expression inhibited the bleomycin-dependent increase in myofibroblasts (Tanaka et 
al., 2010).  
 
Based on those evidences, the expression of HSP70 was investigated by western blots 
using 17-AAG (in vitro) or 17-DMAG (in vivo). The alteration of HSP70 chaperone 
expression was evaluated in the absence or presence of 17-AAG/ 17-DMAG. The 
HSP70 expression increased after treatment with HSP90 inhibitor in both hILFBs and 
bleomycin-administrated mice when compared with untreated control or sham control, 
respectively. It is known that HSP70 exhibits antiapoptotic effects vie different 
mechanisms such as binding to apoptotic protease activating factor 1 (Apaf-1) in order 
to prevent the activation of caspase-9 and suppress downstream of apoptotic pathway 
of caspase-3 activation. Further, it was recently demonstrated that HSP70 blocks the 
activation of Bcl-2-associated X protein (BAX), which is crucial for apoptosis-associated 
mitochondrial dysfunction (Suemasu et al., 2009). This mechanism might be 
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considered as a crucial in the HSP70-dependent suppression of bleomycin-induced 
lung epithelial cell apoptosis. It is well documented  that BAX and caspases activation 
play the important role in bleomycin-induced apoptosis in epithelial cells (Lee et al., 
2005). Additionally, it might be possible that HSP70 exhibits inhibitory effects on EMT 
via the inhibition of NF-ҡB. There are  many reports indicating that  NF-ҡB stimulates 
EMT independently on TGF-β1 (Lee et al., 2005).  
 
5.7. HSP90 regulates TGFβRs 
Although HSP90 is essential for the viability of healthy cells, cancer cells might demand 
a higher level of HSP90-dependent clients and therefore require an increased level of 
HSP90 activity (Zhao and et al., 2005), as opposed to normal tissues, which may 
provide a favorable therapeutic window. It may also hold true for the fibrotic diseases. 
We found that the antifibrotic effects of HSP90 inhibition were a consequence of 
significant depletion of TGF-βRs on the post-translational level, but not on the 
transcriptional level, followed by decreased Smad2/3 activation. Indeed, present results 
demonstrate that the response to TGF-β1 in terms of fibroblast activation and ECM 
production was greater in ILFBs derived from patients with IPF than in ILFBs from 
donors. However, HSP90 inhibition shows similar potency for cells from both sources, 
suggesting that HSP90 is accountable for the higher sensitivity of the canonical TGF-β-
Smad2/3 pathway in ILFBs derived from patients with IPF compared with donor-
derived cells. Interestingly, recent study has proved that TGF-β signaling is activated in 
SSc (systemic sclerosis) fibroblasts, and also has showed that the overexpression of 
constitutively active TGF-β1 up-regulates HSP90β expression in murine skin (Tomcik 
et al., 2014).   
 
Furthermore, endogenous co-immunoprecipitation proves that TGF-βRII directly 
interacts with HSP90β, indicating that TGF-βRII is a client of HSP90 and can be 
stabilized by HSP90. And the result with MG-132, a proteasome inhibitor, indicates that  
the compromised interaction of HSP90 and TGF-βRs lead to proteasome degradation 
of  TGF-βRs.  In support  of this finding, recent  studies using  epithelial cell  lines have  
demonstrated a direct interaction of TGF-βRs with HSP90 (Zhang et al., 2012), 
(Wrighton et al., 2008). Additionally, the investigators showed that the HSP90 inhibitor 
17-AAG disrupts this interaction and recruits Smurf2 to TGF-βRs which promotes TGF-
βR ubiquitination and subsequent degradation (Zhang et al., 2012). HSP90 chaperone 
machinery maintains protein homeostasis of various set of client proteins either by 
  
DISCUSSION 
93 
 
assisting protein folding and maturation or by stabilizing protein complexes (Taipale et 
al., 2010). 
 
5.8. In vivo studies with 17-DMAG 
The various reports investigated the effectiveness of HSP90 inhibitor in many diseases 
such as systemic sclerosis, LPS-induced lung and liver inflammation as well as renal 
fibrosis. Tomcik and colleagues also showed that HSP90 inhibitor (17-DMAG) prevents 
skin fibrosis induced by overexpression of a constitutively active TGF-β RI. Moreover, 
the 17-DMAG decreases potent antifibrotic effects as well in Tsk-1 mice (they have a 
dominant mutation in the fibrillin-1 gene which occurs in elevated activation of latent 
TGF-β). These results were showed by reduced dermal thickening, hydroxyline content 
and number of myofibroblasts on tissue sections as well as decreased nuclear 
accumulation of phosphorylated  pSMAD2/3 (Tomcik et al., 2014).  
 
Ambade and colleagues also elucidated the role of 17-DMAG in prevention of LPS-
induced liver injury.  They found that pro-inflammatory cytokines, TNF-α and IL-6 were 
significantly blocked at both mRNA and protein level in liver treated with 17-DMAG and 
LPS. Moreover, the inhibition of HSP90 in the liver induces HSF1 (heat shock factor 1) 
and blocked LPS-induced NFҡB activation and pro-inflammatory cytokine production 
attenuating  liver injury (Ambade et al., 2012). Noh and colleagues determined the 
therapeutic efficacy of HSP90 inhibitor in unilateral ureteral obstruction (UUO) kidney 
model of renal fibrosis in mice. They found that the treatment with 17-AAG significantly 
attenuates α-SMA, fibronectin and collagen I in UUO kidneys and restores E-cadherin. 
Finally, the phosphorylation of SMAD2 induced by UUO was decreased by the 
treatment with17-AAG, indicating that these events were dependent on TGF-β1. Lilia 
and colleagues assessed the ability of HSP90 inhibitor (ganetespib) a non-
geldanamycin HSP90 blocker, to suppress LPS-induced proteases, inflammatory 
mediators and cellular infiltrates. Ganetespib also suppressed B cells and  NK cell  
recruitment, MMP9  level  and chemokine and cytokine induction. Further, this inhibitor 
is introduced as a potential inhibitor in therapies for inflammatory diseases, in particular 
those of the lung (Lilja et al., 2015).  
Based on earlier evidence from others and  present in vitro results from my doctoral 
thesis, it is reasonable to speculate that HSP90 may be more than a cancer target, but 
also a target for pulmonary fibrosis. In consistent with expression patterns of human 
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ILFBs, the increased HSP90 expression was observed in ILFBs from bleomycin-
challenged mice.  
17-DMAG, an analogue of 17-AAG, is water soluble and displays high oral 
bioavailability and low toxicity, which make it desirable for therapeutic purposes (Egorin 
et al., 1998). In the bleomycin-challenged mice model, therapeutic dosing (10 mg/kg or 
25 mg/kg, every 2 days) of the small molecular HSP90 inhibitor 17-DMAG was 
demonstrated for the first time. 
 
Further, HSP90 inhibitor in vivo can attenuate experimental pulmonary fibrosis and 
improves lung function. Bleomycin-challenged mice exhibited significant loss of body 
weight compared to sham control, whereas 17-DMAG improved bodyweight, with a 
greater gain of body weight in the higher dose (25 mg/kg)-treated mice. The fibrosis 
scoring and collagen content was decreased in the group treated with 17-DMAG in 
comparison with bleomycin-challenged mice. It was also shown that in unilateral 
ureteral obstruction (UUO) model of kidney fibrosis, the HSP90 inhibitor reduces 
collagen deposition on tissue sections as well as prevents the elevation of TGF-β 
receptor II expression at protein level (Noh et al., 2012).   
 
5.8.1. The role of inflammation in IPF 
The inflammatory response is the initial response following injury challenges and 
fibrosis is generally a final outcome of the inflammatory process in the lung. The 
response is characterized by migration and activation of both resident and circulating 
inflammatory cells, including macrophages, neutrophils, lymphocytes, the production of 
cytokines and growth factors (Gong et al., 2005). Inflammatory and epithelial cells 
release cytokines/growth factors, such as TNF-α, TGF-β, interleukin 1 (IL)-1, 6 and 8, 
insulin-like growth factor (IGF)-1 and platelet-derived growth factor (PDGF) as well as 
stimulate migration, secretory activities and collagen production by fibroblasts. 
Meanwhile, injury causes increased permeability of the pulmonary epithelium and 
endothelium, resulting  in  extravasation of plasma  proteins and ultimately extracellular 
matrix remodeling and fibrin deposition in the alveolar lumen and interstitium (Ou et al., 
2009).  
The changes in cellular profiles in BAL fluid has been well investigated  in bleomycin-
induced fibrosis (Oku et al., 2008).  Kim and collegues demonstrated dose response 
effects of bleomycin on inflammation and pulmonary fibrosis. They found the modest 
increase of the number of neutrophils and leukocytes on day 7, whereas at day 24 the 
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neutrophil number dropped (Kim et al., 2010). In this study, inflammatory cell 
composition in bronchoalveolar lavage fluid (BALF) was evaluated. BALF collected on 
D21 revealed a significant reduced percentage of macrophages in bleomycin-
challenged group compared to sham control and elevated percentage of lymphocytes 
and neutrophils. After treatment with two doses of 17-DMAG, the percentage of 
macrophages was partially restored and the percentage of lymphocytes and 
neutrophils was markedly decreased compared to the bleomycin-challenged mice. 
Taken together, in vivo data suggest that 17-DMAG reduces bleomycin-induced 
fibrosis.  
 
5.8.2.  The role of matrix metalloproteinases in IPF 
MMP is a key element of tissue repairing, cell invasion and epithelium basement 
membrane destruction (Dancer et al., 2011)(Clarke et al., 2013). Fluorogenic MMP 
substrates noninvasively present that tumors have elevated MMP activity compared to 
non-tumor-bearing animals. Littlepage and colleagues suggest distinct contribution by 
MMPs to the progression of aggressive prostate tumour and to helping tumours 
cleverely find alternative route for malignant progression (Littlepage et al., 2010). 
Further, these fluorogenic MMP substrates can directly assess the efficacy of MPIs 
(MMP inhibitors) on MMP activity in intact tumors in vivo. Bremer and colleagues show 
for the first time that the effect of MMP inhibition can be directly imaged within hours 
after the initiation of treatment using the potent MMP inhibitor, prinomastat (Bremer et 
al., 2001).  
Inhibitors of MMPs have been tested in various animal models of acute and chronic 
inflammation, as well as in invasive cancer because of their potential in therapeutic 
approaches. Several lines of study pointed to models used to study the 
pathophysiology of MMP9. Many inflammatory and vascular animal models were 
developed for human diseases and the effects of inhibitors have been tested by using 
MMP9 inhibitors (Hu et al., 2007).  
 
Matrix metalloproteinases (MMPs) degrade all of the extracellular matrix components 
and may play a role in abnormal alveolar permeability in IPF. MMP1, MMP2 and MMP7 
are the most highly expressed genes in IPF (Zuo et al., 2002). Most of these enzymes 
are localized in epithelial cells, some of them in fibroblast foci. MMP1 is expressed by 
epithelial cells and it is not present in fibroblasts. MMP2 and MMP9 are strongly 
localized in fibroblast foci and involved in the disruption of epithelial basement 
  
DISCUSSION 
96 
 
membrane. The increased level of MMP9 is found in the bronchoalveolar lavage of 
patients suffering from IPF and is attributed to severe clinical phenotype (García-
Alvarez et al., 2006). Additionally, in patients with IPF, impaired balance between 
MMPs and TIMPs (tissue inhibitor of matrix metalloproteinases) is affected by oxygen 
species.  A profibrotic environment is promoted by reactive oxygen species that induce 
the imbalance between MMPs and tissue inhibitors of metalloproteinases (TIMP) and 
activate TGF-β (Kinnula et al., 2005).  
Several studies have suggested that there is an increase in MMPs, rather than a loss 
of MMPs, in IPF (McKeown et al., 2009).  In this context, the total pulmonary MMP 
activity was examined using fluorescence molecular tomographic (FMT) imaging, a 
state-of-art in vivo imaging technology. To monitor the metalloproteinase (MMP) activity 
by fluorescence molecular tomography (FMT) in the response to the 17-DMAG 
treatment in vivo, a MMP activable probe (MMP680Sense) was introduced. The 
fluorescence signal that reflected MMP activity was elevated in mice administrated with 
bleomycin The treatment with the lower dose of 17-DMAG slightly decreases the 
activity of enzyme, whereas the high dose markedly reduces the activity of MMPs 
These data showed that the treatment with 17-DMAG diminishes the activity of MMPs 
in bleomycin- induced fibrosis. 
 
5.9. Links of idiopathic pulmonary fibrosis to cancer biology 
It has been recently hypothesized that IPF might be considered as a neoproliferative 
disorder of the lung because it exhibits several pathogenic similarities to cancer. 
Epigenetic and genetic abnormalities, altered cell-cell communication, uncontrolled 
proliferation and tissue invasion are fundamental biological hallmarks characterizing 
both IPF and cancer. Such vision can help to identify new pathogenic mechanisms 
borrowed from cancer biology, leading to new and more effective approaches 
(Vancheri, 2012).  
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6. CONCLUSIONS 
Based on the current study, the mechanism by which HSP90 promotes pulmonary 
fibrosis, is presented in the schematic diagram presented in Figure 31.  Excessive 
TGF-β1, a highly pro-fibrotic cytokine, binds to TGF-βRII and forms a complex together 
with TGF-βRI, which is stabilized by HSP90 interaction. The activated TGF-βRI kinase 
phosphorylates Smad2/3, which subsequently recruits Smad4, and translocates into 
nucleus to initiate expression of fibrotic genes.  
 
On the other hand, HSP90 inhibitor (eg. 17-AAG or 17-DMAG) blocks HSP90 and 
prevents the formation of HSP90/TGF-βRs complex, thus promotes degradation of 
TGFβRs in proteasomes. This terminates the TGF-β signaling pathway and blocks 
transdifferentiation of myofibroblasts from fibroblasts or epithelial cells in the lung. 
 
 
 
Figure 31. Schematic diagram for the proposed mechanism by which HSP90 promotes pulmonary 
fibrosis. HSP90 (heat shock protein 90); TGF-β R: transforming growth factor receptor; TGF-β: 
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transforming growth factor; 17-DMAG: 17-(Dimethylaminoethylamino - 17 -demethoxygeldanamycin; 17-
AAG: 17-Allylamino-17-demethoxygeldanamycin.  
 
In conclusion, for the first time a pathogenic role of HSP90 was demonstrated in 
pulmonary fibrosis by manipulating TGF-β-Smad2/3 signaling in vitro and in vivo. The 
clinical implications of the findings are profound, because the profibrotic phenotype 
features are sensitized through HSP90 machinery in pulmonary fibrosis, which may 
present therapeutic advantages of HSP90 inhibitors in treating IPF. 
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7. PROSPECTIVES 
The role of TGF-β in the pathogenesis of IPF has been well characterized. TGF-β is 
actively involved in initiation and progression of the pulmonary fibrosis (Leask and 
Abraham, 2004); (Fernandez and Eickelberg, 2012b). More comprehensive study with 
TGF-β receptors overexpressing mice are clearly required in the future. The gain-of-
function experiments seem to be helpful to elucidate the association between TGF-β 
receptors and HSP90 in pulmonary fibrosis. Tomcik and colleagues demonstrated in 
replication-deficient adeno-associated virus encoding constitutively active TGF-β 
receptor I, that 17-AAG reduced dermal thickening, collagen deposition and reduced 
number of myofibroblast in dermal fibrosis (Tomcik et al., 2014). 
 
In this study only TGF-β receptor I and II were investigated as a client protein for 
HSP90. It may also be necessary to introduce new profibrotic clients, with the 
emphasis on those which can be used in the animal model. Haupt and colleagues have 
been able to classify 64 kinases as true HSP90 clients with the strong representation of 
pathways associated with tumour progression like the BMP, MAPK and TGF-β 
signaling cascades. It is of interest to discover new HSP90 clients, which could provide 
new opportunities for the treatment of pulmonary fibrosis and diagnostic applications 
(Haupt et al., 2012).  
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8. LIMITATIONS OF THE STUDY 
There were limitations to this study. First, the in vivo experiment were designed in the 
model of bleomycin-induced fibrosis. Although this model is used the most frequently, it 
has been known to have some disadvantages. The lung fibrosis is resolved after 28 
days when bleomycin is delivered by intratracheal route. Further, the inflammatory 
phase occurs within first week, therefore to study the effects of antifibrotic agents, the 
therapy should be introduced after this phase (B. Moore et al., 2013). In contrast to 
human lung fibrosis, this model does not reveal a prominence of hyperplastic AECs 
lining the areas of fibrosis which is the characteristic of usual interstitial pneumonia 
(UIP) (Degryse et al., 2010). 
 
Second, the effect of HSP90 inhibitor on rescuing epithelial cells from apoptosis have 
been not investigated in this study. Many lines of evidence prove that lung fibrosis is 
associated with alveolar epithelial cell death and excessive lung fibroblast proliferation 
(King Jr et al., 2011; Todd et al., 2012).   
 
Third, in this study canonical TGF-β signaling pathways was only the focus of atention. 
In the non-canonical pathways, the activated TGF-β receptor complex transmits a 
signal through other factors such as: p38 MAPK, RHO, PI3K-AKT, ERK, JNK, NF-κB 
(Akhurst and Hata, 2012). Noh and colleagues elucidated that the treatment with 17-
AAG inhibited the phosphorylation of SMAD2, AKT, GSK-3β and ERK in a time-
dependent manner (Noh et al., 2012). Their findings suggest that 17-AAG may act via 
different mechanism to block TGF-β1- induced signaling. 
 
Fourth, the gain-of-function experiments were not carried out. The study of the HSP90 
overexpression might elucidate its impact on migration and collagen deposition as well 
as the change of profibrotic markers such as collagen I, fibronectin, pSMADs and TGF-
β 1 receptors.  
 
Fifth, it was not possible to carry out in vivo experiments with HSP90 KO due to lack of 
HSP90 knockout mice. Unfortunately, mammalian Hsp90 is encoded by two genes, 
Hsp90α and Hsp90β, which are thought to be functionally similar and redundant. The 
Hsp90β knockout mouse exhibits early embryonic lethality, whereas Hsp90α-deficient 
mice occurs in adult males which exhibit a failure of spermatogenesis (Grad et al., 
2010; Sanchez, 2012).  
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9. SUMMARY 
Idiopathic pulmonary fibrosis (IPF) is a progressive, chronic and usually lethal lung 
disease of unknown causes with limited therapeutic options. Active myofibroblasts in 
the intestinal and fibroblast foci are responsible for excessive tissue remodeling in 
response to recurrent alveolar epithelial micro-injuries. Although the underlying 
mechanisms of IPF are not fully understood, transforming growth factor beta 1 (TGF-
β1) is recognized as the key player in disease progression. HSP90 is a highly 
conserved chaperone protein and is essential for stabilization or degradation of many 
signaling proteins. HSP90 is centrally involved in the pathobiology of cancer and 
HSP90 inhibitors have been widely investigated in preclinical and clinical studies 
against cancer. Recent evidence shows that HSP90 promotes epithelial-mesenchymal 
transition (EMT) of cancer cells and TGF-β1 signaling via the stabilizing of the TGF-β 
receptors, however little is known about the role of HSP90 in IPF.  
 
The purpose of the present study is to discover the role of HSP90 in lung fibroblast 
activation, particularly with regard to TGF-β1-induced profibrotic phenotype, and to 
determine the effects of HSP90 inhibitor on bleomycin-induced pulmonary fibrosis in 
mice.   
 
Immunohistochemistry demonstrated intensive immunoreactivity of HSP90 in activated 
pulmonary fibroblasts in lungs from IPF patients. Moreover, the expression profiling 
using western blot showed a significant upregulation of HSP90α and HSP90β in lungs 
as well as primary interstitial lung fibroblasts (ILFBs) derived from IPF patients when 
compared with donors. Those finding directed the study at effects of HSP90 inhibition 
on lung fibroblast activation and fibrotic response in vitro.  
 
Both resident fibroblasts and alveolar epithelial cells are sources of lung myofibroblasts 
via cytokine-induced transdifferentiation. TGF-β1, as such a crucial cytokine promoting 
fibrosis, was used to induce fibroblast activation and EMT of A549 cells in the in vitro 
study. 17-AGG, a selective HSP90 inhibitor, blocked ILFBs activation and collagen 
production induced by TGF-β1, as demonstrated by western blot of α-SMA expression 
and Sircol Soluble Collagen assay, respectively. In addition, transwell assay showed 
that 17-AAG inhibited ILFBs migration induced by serum. Interestingly, 17-AAG also 
prevented EMT of A549 cells induced by TGF-β1, revealed by western blot and 
immunofluorescence staining of mesenchymal and epithelial markers. 
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Furthermore, the diminished protein level of TGF-β RI and/or TGF-β RII was observed, 
along with less Smad2 phosphorylation after treatment with 17-AAG in both ILFBs and 
A549 cells stimulated with TGF-β1. In addition, co-immunoprecipitation confirmed a 
direct interaction between TGF-β RII and HSP90β in ILFBs, which implies that TGF-β 
receptors are clients of HSP90 and are stabilized by HSP90. And the result with MG-
132, a proteasome inhibitor, indicates that the compromised interaction of HSP90 and 
TGF-βRs leads to proteasomal degradation of TGF-βRs. 
 
In light of the promising in vitro effects, the in vivo effects of the highly selective HSP90 
inhibitor (17-DMAG) was evaluated in attenuation of pulmonary fibrosis, using the 
established bleomycin-induced pulmonary fibrosis mouse model. Western blot showed 
increased expression of HSP90 in ILFBs from bleomycin-challenged mice as compared 
to sham control. Treatment with 17-DMAG (10 or 25 mg/kg) for 14 days was carried out 
7 days after bleomycin challenge. 17-DMAG rescued the bodyweight loss and 
improved the lung compliance. Pulmonary inflammation induced by bleomycin was 
attenuated by 17-DMAG treatment, indicated by inflammatory cell composition from 
bronchoalveolar lavage fluid (BALF) and less active matrix metalloproteases (MMPs) 
measured by in vivo fluorescence molecular tomography (FMT) in combined with 
micro-computed tomography (µCT). Histological assessment including Ashcroft fibrosis 
scoring and collagen deposition all suggested that 17-DMAG ameliorates bleomycin-
induced pulmonary fibrosis. 
 
Taken together, this study supports a central role of HSP90 in progressive pulmonary 
fibrosis by manipulating TGF-β/Smad signaling and suggests a therapeutic potential of 
HSP90 inhibitors against IPF. 
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10. ZUSAMMENFASSUNG 
Die idiopathische pulmonale Fibrose (IPF) ist eine fortschreitende, chronische und 
meist tödlich verlaufende Erkrankung mit unbekannter Ursache und wenigen 
Therapieoptionen. Aktivierte Myofibroblasten in fibrotischen Zentren sind für die 
exzessiven Gefäßveränderungen verantwortlich, welche in Folge von sogenannten 
Mikro-Verletzungen im alveolaren Epithel stattfinden. Obwohl die grundlegenden 
Mechanismen der IPF noch nicht vollständig aufgeklärt sind, wurde das Zytokin TGF-
β1 (Transforming growth factor beta 1) bereits als ein wichtiges Schlüsselprotein in der 
Entstehung der Lungenfibrose identifiziert. 
 
Hsp90 (heat shock protein 90) ist ein hoch konserviertes Chaperone-Protein und trägt 
zur Regulation der Stabilisierung und Degradation von vielen Signalproteinen bei. 
Hsp90 spielt des Weiteren in der Pathobiologie von Tumoren eine entscheidende Rolle 
und entsprechende Hsp90-Inhibitoren werden zurzeit in klinischen Studien in der 
Krebstherapie untersucht. Neueste Erkenntnisse zeigen, dass Hsp90 die zelluläre 
Umwandlung von Tumorzellen vom epithelialen zum mesenchymalen Phänotyp  (EMT: 
epithelial-to-mesenchymal transition) durch eine Stabilisierung der TGF-β-Rezeptor-
Proteine und damit die Aktivierung des nachgeschalteten TGF-β1-Signalweges 
unterstützt. Ob Hsp90 im Falle der IPF den TGF-β1 Signalweges auf die gleiche Weise 
reguliert, ist allerdings noch unklar. 
 
Ziel der hier vorgelegten Doktorarbeit ist es, die Rolle von Hsp90 in der Aktivierung der 
pulmonalen Fibroblasten zu untersuchen. Dabei ist besonders  der TGF-β1-induzierte 
pro-fibrotische Phänotype  von Interesse. Des Weiteren soll ein Hsp90-inhibitor im 
Mausmodell der Bleomycin-induzierten Lungenfibrose auf seine therapeutische 
Effektivität getestet werden. 
 
Die immunhistochemische Analyse von Lungen von IPF-Patienten zeigte eine 
deutliche Immunoreaktivität von spezifischen anti-Hsp90-Antikörpern in aktivierten 
pulmonalen Fibroblasten. Mittels Western-Blot-Verfahren konnte eine signifikante 
Erhöhung der Proteinexpression der beiden Hsp90-Isoformen, Hsp90α und Hsp90β, in 
Lungenhomogenisaten und primären, interstitiellen Lungenfibroblasten (ILFB: 
interstitial lung fibroblasts) von IPF-Patienten im Vergleich zu gesunden Donoren 
festgestellt werden. Die Daten dienten als Ausgangpunkt für die Untersuchungen von 
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Hsp90-Inhibitoren auf die Aktivierung von Lungenfibroblasten und dessen pro-
fibrotische Reaktion in Zellkulturversuchen in vitro. 
Sowohl gewebsständige Fibroblasten als auch alveolare Epithelzellen können sich 
über Zytokin-induzierte Transdifferenzierung zu pulmonalen Myofibroblasten 
entwickeln. Das pro-fibrotische Zytokin TGF-β1 wurde in den in vitro-Studien 
verwendete, um diese Fibroblasten-Aktivierung und die EMT von A549-Zellen 
(abgeleitet aus einem Adenokarzinom von humanem alveolaren Basal-Epithelzellen) 
auszulösen. Der selektive Hsp90-Inhibitor, 17-AAG, blockierte die TGF-β1-abhängige 
ILFB-Aktivierung und Kollagen-Synthese, was in Western-Blot-Analysen auf 
Myofibroblast-Markerproteine  und einem Sircol-Kollagen-Test gezeigt werden konnte. 
Zusätzlich konnte in einem Transwell-Migrationstest die 17-AAG-vermittelte Inhibition 
der Serum-induzierten ILFB-Migration nachgewiesen werden. Auch die TGF-β1-
induzierte EMT von A549-Zellen ließ sich durch die Zugabe von 17-AAG hemmen. Als 
Techniken kamen hier das Western-Blot-Verfahren und eine Immunfluoreszenz auf 
spezifische mesenchymale und epitheliale Marker zur Anwendung.  
 
Zusätzlich konnte eine Abnahme der Expression des TGF-β1-Rezeptor I und/oder II in 
Kombination mit einer reduzierten Smad2-Phosphorylierung nach der Verabreichung 
von 17-AAG in beiden Zellsystemen, ILFB und A549, in vitro beobachtet werden. Eine 
Ko-Immunpräzipitation bestätigte eine direkte Protein-Protein-Interaktion des TGF-β1-
Rezeptor II mit dem Chaperone Hsp90 in ILFB, was zu der Vermutung führte, dass der 
Rezeptor ein sogenanntes Substrat-Protein (client) für das Chaperone Hsp90 ist und 
dass der TGF-β1-Rezeptor II durch diese proteinbiochemische Bindung stabilisiert 
bzw. vor einer Degradation geschützt wird. Versuche mit dem Proteasom-Inhibitor MG-
132 konnten zeigen, dass es sich um eine proteasomale Degradation der TGF-β1-
Rezeptoren nach ihrer erfolgten Bindung an Hsp90 handelt. 
 
Aufgrund der vielversprechenden in vitro Daten wurde der 17-AAG-verwandte Hsp90-
inhibitor, 17-DMAG, im etablierten Mausmodell der Bleomycin-induzierten IPF auf sein 
therapeutisches Potential hin untersucht. Die Western-Blot-Analyse der ILFB zeigte 
einen deutlichen Anstieg der Hsp90-Expression in Bleomycin-verabreichten Mäusen im 
Vergleich zu gesunden Tieren. Die Behandlung mit 17-DMAG (mit 10 bzw. 25 mg/kg 
Körpergewicht) erfolgte ab dem 7. Tag nach Bleomycin-Gabe für die folgenden 14 
Tage. Dabei konnte eine Gewichtsreduktion, wie sie üblicherweise unter Bleomycin-
Verabreichung zu beobachten ist, verhindert und ein wesentlicher Parameter für die 
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Lungenfunktion, d.h. die Lungen-Dehnbarkeit (Compliance) verbessert werden. Die 
Analyse der broncho-alveolaren Spülflüssigkeit (BALF: bronchoalveolar lavage fluid) 
zeigte eine verminderte Präsenz von inflammatorischen Zellen in den Tieren, denen 
neben Bleomycin gleichzeitig auch 17-DMAG verabreicht wurde. Mittels einer Echtzeit-
FMT-µCT-Messung (fluorescence molecular tomography combined with micro-
computed tomography) konnte in diesen Tieren ebenfalls eine reduzierte Aktivität der 
Matrix-Metalloproteasen in vivo gemessen werden. Diese Ergebnisse deuteten darauf 
hin, dass eine 17-DMAG-Behandlung die durch Bleomycin-ausgelöste 
sInflammationsreaktion abgeschwächt hat. Eine histologische Untersuchung inklusive 
der Einstufung auf der Ashcroft-Fibrose-Skala und die Bestimmung der Kollagen-
Deposition ließen vermuten, dass der Hsp90-Inhibitor, 17-DMAG, die Entstehung der 
Bleomycin-induzierten pulmonalen Fibrose verhindern bzw. verzögern kann. 
 
Zusammengefasst lässt sich sagen, dass die hier vorgestellten Ergebnisse zum einen 
unzweifelhaft eine zentrale Rolle von Hsp90 in der fehlgeleiteten Regulation des TGF-
β1/Smad-Signalweges  in der pulmonalen Fibrose demonstrieren. Zum anderen wird 
das therapeutische Potential einer entsprechenden Hsp90-Inhibition, wie z.B. durch 17-
DMAG, in der Behandlung der IPF am Beispiel des murinen Bleomycin-Modells 
aufgezeigt. 
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11. ABBREVIATIONS 
17-AAG - 17-Allylamino-17-demethoxygeldanamycin  
17-DMAG - 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin  
AD - Alzheimer’s disease  
AEC - alveolar epithelial cell  
AHA1 - activator of HSP90 ATPase 1  
ALKs - activing- receptor-like kinase  
AP - Alkaline phosphatase  
APS - ammonium persulfate   
ATF6 - activating transcription factor 6 
ATP - adenosine triphosphate  
BAL - bronchoalveolar lavage  
bFGF - basic fibroblast growth factor  
BMP - bone morphogenetic protein   
BS3 - bis(sulfosuccinimidyl)suberate  
BSA - bovine serum albumin  
CC10 - Clara cell 10  
CDC37 - cycle 37 homologue  
cDNA - complementary deoxyribonucleic acid 
CHOP - CCAAT/enhancer-binding protein (C/EBP) homologous protein 
COD - coefficient of determination  
co-SMADs - common partner SMADs  
Ct - threshold cycle 
CTD - c-terminal domain   
CTGF - connective tissue growth factor 
CXCL10 - chemokine (c-x-c) motif ligand 10 
CXCR4 - C-X-C chemokine receptor 4  
Da - dalton 
DAPI - 4’,6-diamidino-2-phenylindole 
DLCO - diffusing capacity of the lung for carbon monoxide 
DPLD - diffuse parenchymal lung disease  
DT - diphtheria toxin  
DTT - dithiothreitol  
EBV - Epstein-Barr virus  
ECL - enhanced chemiluminescence  
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EDTA - ethylenediaminetetraacetic acid  
EGF - human epidermal growth factor  
EMT - epithelial - mesenchymal transition  
eNOS - endothelial nitric-oxide synthase 
ER stress - endoplasmic reticulum stress 
et al. - et alii (and others) 
FITC - fluorescein isothiocyanate  
FMT- fluorescence molecular tomography  
FOT - forces oscillation technique  
FVC - forced vital capacity  
FXa - factor Xa 
g - gram 
GER - gastroesophageal reflux 
GM - benzoquinone ansamycin geldanamycin  
GRP94 - glucose-regulated protein 94  
HIF - hypoxia inducible factor 
hILFBs- human interstitial lung fibroblasts  
HRP - horse radish peroxidase  
HSP90α A1- hsp90α class a1  
HSP90α B1- hsp90α class b1  
HX - histiocytosis x  
IFN-γ - interferon-γ 
IIP - idiopathic interstitial pneumonia  
IL - interleukin 
IPF - idiopathic pulmonary fibrosis 
IRE1α - inositol requiring enzyme 1α 
i-SMADs - inhibitory SMADs 
kb - kilo base pairs 
KCl - potassium chloride  
kDa -  kilo dalton 
KH2PO4 - monopotassium phosphate  
LAM - lymphangioleiomyomatosis  
LAP - latency associated peptide  
lLB - luria broth  
LTBP - latent TGF-β-binding proteins  
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LTGF-β - latent precursor molecules of TGF- β  
M - molar (mole/litre) 
MAPK - mitogen-activated protein kinase  
MD - middle-domain  
mg - milligram 
min - minute(s) 
miRNA - microRNA 
ml - milliliter 
mM - millimolar 
MMP - matrix metalloproteinase  
MUC5B - mucin 5B 
NA2HPO4 x H2O - disodium phosphate dihydrate 
NaCl - sodium chloride  
NADPH - nicotinamide adenine dinucleotide phosphate-oxidase  
NALP3 - NACHT and LRR, PYD domains-containing protein 3  
nm - nanometer 
nM - nanomolar 
NO - nitric oxide  
NQO1 - NADPH quinone oxidoreductase 1  
NTD - n-terminal domain  
PaO2 - partial pressure of oxygen in arterial blood 
PBS - phosphate-buffered saline  
PCR - polymerase chain reaction 
PDGF- platelet-derived growth factor 
PERK - protein kinase RNA-like ER kinase 
PFA - paraformaldehyde  
PGE2 - prostaglandin E2 
qRT-PCR -  quantitive realtime- polymerase chain reaction  
RD - macrolactone radicicol  
ROS - reactive oxygen species 
RPM - revolution per minute 
RT - room temperature 
SARA - anchor for receptor activation  
SDS-PAGE - SDS-polyacrylamide gel electrophoresis   
SP-C - surfactant protein C 
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TBST - Tris-buffered saline and Tween 20 
TEMED - tetramethylethylenediamine  
TERC - telomerase RNA template component 
TERT - reverse transcriptase component  
TF - tissue factor 
TGF-β receptor - transforming growth factor receptor  
TIMP - tissue inhibitor of metalloproteinases  
TNF - tumor necrosis factor 
TRAP1 - tumour necrosis factor receptor-associated protein 1   
UIP - usual interstitial pneumonia  
UPR - unfolded protein response  
V - volt 
VCAM-1 - vascular cell adhesion molecule-1  
VEGF - vascular endothelial growth factor 
VEGFR2 - vascular endothelial growth factor receptor 2  
α-SMA - alpha smooth muscle actin  
µCT - micro computed tomography  
µg - microgram 
µl - microliter 
µm - micrometer 
µM - micromolar 
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